US20090233345A1 - Catalytic domains of beta(1,4)-galactosyl transferase i having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use - Google Patents

Catalytic domains of beta(1,4)-galactosyl transferase i having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use Download PDF

Info

Publication number
US20090233345A1
US20090233345A1 US12/321,006 US32100609A US2009233345A1 US 20090233345 A1 US20090233345 A1 US 20090233345A1 US 32100609 A US32100609 A US 32100609A US 2009233345 A1 US2009233345 A1 US 2009233345A1
Authority
US
United States
Prior art keywords
galactosyltransferase
udp
donor
protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/321,006
Inventor
Pradman Qasba
Boopathy Ramakrishnan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to US12/321,006 priority Critical patent/US20090233345A1/en
Publication of US20090233345A1 publication Critical patent/US20090233345A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01133—Xylosylprotein 4-beta-galactosyltransferase (2.4.1.133)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)

Definitions

  • the invention relates generally to ⁇ (1,4)-galactosyltransferase I mutants having altered donor and acceptor specificities, and methods of use thereof.
  • the invention relates to methods for using the ⁇ (1,4)-galactosyltransferase I mutants to increase the immunogenicity of an antigen, such as vaccines, and for synthesizing saccharide compositions.
  • Oligosaccharides are chains composed of saccharide units, which are commonly known as sugars. Of the biological polymer families, oligosaccharides are the least studied, due in part to the difficulty of sequencing and synthesizing their complex sugar chain. Currently, no generally applicable synthetic technique for synthesizing oligosaccharides is available.
  • oligosaccharides that have the same sugar sequence and stereochemistry found on the active portion of a glycoprotein or glycolipid involved in the interactions.
  • the oligosaccharides are believed to compete with the glycoproteins and glycolipids for binding sites on the receptor proteins.
  • the disaccharide galactosyl- ⁇ (1,4)-N-acetylglucosamine is believed to be one component of the glycoprotein which interacts with receptors in the plasma membrane of liver cells.
  • oligosaccharides and other saccharide compositions that mimic ligands recognized and bound by cellular receptors are thought to be useful in applications that include diagnostics and therapeutics.
  • Anti-Gal a naturally occurring antibody present in all humans, specifically interacts with the carbohydrate epitope Gal- ⁇ (1-3)Gal- ⁇ (1-4)GlcNAc-R ( ⁇ -galactosyl epitope). This antibody does not interact with any other known carbohydrate epitope produced by mammalian cells (Galili, Springer Seminar Immunopathology, 15:153 (1993)). Anti-Gal constitutes approximately 1% of circulating IgG (Galili et al., J. Exp.
  • oligosaccharides There has been relatively little effort to test oligosaccharides as therapeutic agents for humans or animal diseases however, as methods to synthesize oligosaccharides have been unavailable as noted above. Limited types of small oligosaccharides can be custom-synthesized by organic chemical methods, but the cost of such compounds is typically prohibitively high. In addition, it is very difficult to synthesize oligosaccharides stereospecifically and the addition of some sugars, such as sialic acid and fucose, has not been effectively accomplished because of the extreme lability of their bonds. Improved, generally applicable methods for oligosaccharide synthesis are thereby desired for the production of large amounts of widely varying oligosaccharides for therapeutic purposes. Accordingly, the present invention provides enzymes and methods that can be used to promote the chemical linkage of numerous sugars that have previously been difficult to link.
  • the invention provides altered ⁇ (1,4)-galactosyltransferase I catalytic domains that catalyze the formation of a glucose- ⁇ (1,4)-N-acetylglucosamine bond at a greater rate than the catalytic domain of the corresponding wild-type enzyme.
  • the invention also provides ⁇ (1,4)-galactosyltransferase I catalytic domains that catalyze formation of N-acetylgalactosamine- ⁇ (1,4)-N-acetylglucosamine bonds; N-acetylgalactosamine- ⁇ (1,4)-glucose bonds; N-acetylglucosamine- ⁇ (1,4)-N-acetylglucosamine bonds; mannose- ⁇ (1,4)-N-acetylglucosamine bonds; and galactose- ⁇ (1,4)-N-acetylglucosamine-6-SO 3 bonds.
  • the invention also provides polypeptides that contain each of the aforementioned catalytic domains.
  • amino acid segments that promote in vitro folding of catalytic domains of galactosyltransferases, such as ⁇ (1,4)-galactosyltransferase I, and mutants of galactosyltransferases.
  • the invention provides nucleic acid segments that encode the aforementioned ⁇ (1,4)-galactosyltransferase I catalytic domains.
  • Expression cassettes and cells that include nucleic acid segments that encode the aforementioned ⁇ (1,4)-galactosyltransferase I catalytic domains are also provided.
  • a glucose- ⁇ (1,4)-N-acetylglucosamine moiety an N-acetylgalactosamine- ⁇ (1,4)-N-acetylglucosamine moiety; an N-acetylgalactosamine- ⁇ (1,4)-glucose moiety; an N-acetylglucosamine- ⁇ (1,4)-N-acetylglucosamine moiety; a mannose- ⁇ (1,4)-N-acetylglucosamine moiety; and a galactose- ⁇ (1,4)-N-acetylglucosamine-6-SO 3 moiety.
  • the invention also provides methods to increase the immunogenicity of an antigen, and methods to prepare an oligosaccharide composition, including those having a defined sequence.
  • oligosaccharides produced through use of the catalytic domains and methods disclosed herein.
  • FIG. 1 illustrates the catalytic activity of the wt-Gal-T1 and the mutants Y289L, Y289I, and Y289N.
  • A Gal-T activity of wt-Gal-T1 and of mutants at the saturating concentrations of ⁇ -benzyl-GlcNAc as the acceptor.
  • B GalNAc-T activity of the wt-Gal-T1 and of mutants. The activities are measured with 50 mM ⁇ -benzyl-GlcNAc as acceptors at different concentrations of the donor.
  • the Gal-T activity of the wt-Gal-T1 was measured with only 10 mM ⁇ -benzyl-GlcNAc because it exhibited inhibition at 50 mM concentration.
  • FIG. 2 illustrates the partial 1 H NMR spectrum of the disaccharide (LacdiNAc) product from the GalNAc-T reaction with GlcNAc as the acceptor.
  • the signal for the GalNAc anomeric proton is at ⁇ 4.58 ppm and for the GlcNAc anomeric proton corresponding to an ⁇ and ⁇ conformer is at ⁇ 5.2 and 4.7 ppm.
  • the signals from the acetyl group of each sugar moiety are at ⁇ 2.05 and 2.08 ppm.
  • FIG. 3 illustrates the cDNA sequence of the inserts and the derived protein sequences of the constructs in the pET23a vector used for studying the effect of the N-terminal stem region (SR) on the solubility and folding of the catalytic domain (CD) of ⁇ 4Gal-T.
  • SR N-terminal stem region
  • CD catalytic domain
  • An 11 amino acid extension (not shown) is located at the amino-terminal end of the protein and is coded by the pET23a vector leader sequence.
  • the stem region sequence is shaded, followed by the catalytic domain (CD) sequence.
  • the primers used for PCR amplification are underlined.
  • FIG. 4 shows an SDS-PAGE analysis of the recombinant CD and SRCD proteins of ⁇ b 4 Gal-T produced in E. coli .
  • Purified inclusion bodies were analyzed on 14% SDS-PAGE.
  • FIG. 5 shows folding of inclusion bodies under different renaturation conditions: the relative activities of CD ⁇ 4Gal-T1 and SRCD ⁇ 4Gal-T1.
  • the relative activity was calculated with respect to the folding condition I.
  • the largest amount of folded CD ⁇ 4Gal-T1 and SRCD ⁇ 4Gal-T1 was obtained under condition VIII.
  • the enzyme activity under condition I for CD ⁇ 4Gal-T1 was 0.052 pmol/min/ng, and for SRCD ⁇ 4Gal-T1 0.09 pmol/min/ng of N-acetyllactosamine.
  • FIG. 6 shows analysis of the soluble proteins obtained after renaturation of inclusion bodies by SDS-PAGE electrophoresis.
  • ⁇ native conditions
  • (+ samples boiled in the presence of ⁇ -ME.
  • Lane 1 bovine CD ⁇ 4Gal-T1
  • Lane 2 bovine SRCD ⁇ 4Gal-T1
  • Lane 3 human CD ⁇ 4Gal-T1
  • Lane 4 human SRCD ⁇ 4Gal-T1.
  • a portion of the soluble SRCD sample representing misfolded proteins does not enter the gel (arrow 1 in lanes 2 and 4).
  • FIG. 7 illustrates binding and characterization of folded CD ⁇ 4Gal-T1 and SRCD ⁇ 4Gal-T1 on UDP-agarose columns.
  • the purity of the proteins was judged using SDS-PAGE analysis under native conditions in the absence of #ME and without boiling the samples.
  • Panel (A) shows the results with the human CD ⁇ 4Gal-T1 before and after passing through the UDP-agarose column, (bovine CD ⁇ 4Gal-T1 [not shown] behaves in the same way).
  • Panel (B) shows the results with bovine SRCD ⁇ 4Gal-T1
  • Panel (C) shows the results with human SRCD ⁇ 4Gal-T1.
  • the arrows at the top of the lanes in panels B and C show the presence of soluble but misfolded proteins.
  • FIG. 8 shows the enzymatic activity of the soluble human and bovine SRCD ⁇ 4Gal-T1 proteins before and after UDP-agarose purification.
  • the galactosyltransferase activities were measured as described herein. Specific activities of these proteins before binding (( ⁇ ), black bars) and of the eluates after passing through the UDP-agarose column ((+), cross-hatched bars) are shown.
  • Buffer condition I (without PEG-4000 and L-arginine), showed more misfolded molecules in the human SRCD ⁇ 4Gal-T1 compared to bovine SRCD ⁇ 4Gal-T1.
  • Condition VIII (with PEG-4000 and L-arginine) showed more properly folded proteins in the human SRCD ⁇ 4Gal-T1 compared to bovine SRCD ⁇ 4Gal-T1 (black bars).
  • CD ⁇ 4Gal-T1 showed difference in the amounts of folded proteins before and after binding on the UDP-agarose columns either with folding condition I or condition VIII (data not shown).
  • FIG. 9 is a schematic diagram of the in vitro folding of CD and SRCD domains of ⁇ 4Gal-T1.
  • the unfolded CD and SRCD domains during the in vitro folding step are thought to generate folding intermediates (I) and (II), respectively, which produce misfolded and properly folded molecules.
  • the misfolded molecules of CD, (III) are mostly insoluble and precipitate out, whereas properly folded molecules (IV) are soluble, remain in solution and bind to a UDP-agarose column.
  • SRCD misfolded (III′) and properly folded molecules (IV′) are mostly soluble. Due to the solubility effect of SR domain the proportion of the properly folded SRCD molecules increased during the folding process.
  • ⁇ 1,4)-galactosyltransferase I catalyzes the transfer of galactose from the donor, UDP-galactose, to an acceptor, N-acetylglucosamine, to form a galactose- ⁇ (1,4)-N-acetylglucosamine bond.
  • This reaction allows galactose to be linked to an N-acetylglucosamine that may itself be linked to a variety of other molecules. Examples of these molecules include other sugars and proteins.
  • the reaction can be used to make many types of molecules having great biological significance.
  • galactose- ⁇ (1,4)-N-acetylglucosamine linkages are important for many recognition events that control how cells interact with each other in the body, and how cells interact with pathogens.
  • numerous other linkages of this type are also very important for cellular recognition and binding events as well as cellular interactions with pathogens, such as viruses. Therefore, methods to synthesize these types of bonds have many applications in research and medicine to develop pharmaceutical agents and improved vaccines that can be used to treat disease.
  • the present invention is based on the surprising discovery that the enzymatic activity of ⁇ (1,4)-galactosyltransferase can be altered such that the enzyme can make chemical bonds that are very difficult to make by other methods. These alterations involve mutating the enzyme such that the mutated enzyme can transfer many different types of donors, sugars for example, to many different types of acceptors. Therefore, the mutated ⁇ (1,4)-galactosyltransferases of the invention can be used to synthesize a variety of products that, until now, have been very difficult and expensive to produce.
  • the invention also provides amino acid segments that promote the proper folding of a galactosyltransferase catalytic domain.
  • the amino acid segments may be used to properly fold the galactosyltransferase catalytic domains of the invention and thereby increase their activity.
  • the amino acid segments may also be used to increase the activity of galactosyltransferases that are produced recombinantly. Accordingly, use of the amino acid segments according to the invention allows for production of ⁇ (1,4)-galactosyltransferases having increased enzymatic activity relative to ⁇ (1,4)-galactosyltransferases produced in the absence of the amino acid segments.
  • stem region/catalytic domain ⁇ (1,4)-Galactosyltransferase I SRCD ⁇ 4Gal-T1
  • catalytic domain of ⁇ (1,4)-Galactosyltransferase I CD ⁇ 4Gal-T1
  • ⁇ (1,4)-Galactosyltransferase I ⁇ 4Gal-T1
  • catalytic domain CD
  • stem region SR
  • galactosyltransferase activity Gal-T
  • beta-mercaptoethanol ⁇ -ME
  • N-acetylgalactosamine transferase activity GalNAc-T
  • acceptor refers to a molecule or structure onto which a donor is actively linked through action of a catalytic domain of a galactosyltransferase, or mutant thereof.
  • acceptors include, but are not limited to, carbohydrates, glycoproteins, and glycolipids.
  • catalytic domain refers to an amino acid segment which folds into a domain that is able to catalyze the linkage of a donor to an acceptor.
  • a catalytic domain may be from, but is not limited to, bovine ⁇ (1,4)-Galactosyltransferase I (Seq ID NO: 5), the catalytic domain from human ⁇ (1,4)-Galactosyltransferase I (Seq ID NO: 3), or the catalytic domain from mouse ⁇ (1,4)-Galactosyltransferase I (Seq ID NO: 4).
  • a catalytic domain may have an amino acid sequence found in a wild-type enzyme, or may have an amino acid sequence that is different from a wild-type sequence.
  • a catalytic domain may have an amino acid sequence that corresponds to amino acid residues 130402 of SEQ ID NO: 5, expect that the lysine is exchanged with arginine at amino acid position 228.
  • donor refers to a molecule that is actively linked to an acceptor molecule through the action of a catalytic domain of a galactosyltransferase, or mutant thereof.
  • a donor molecule can include a sugar, or a sugar derivative. Examples of donors include, but are not limited to, UDP-galactose, UDP-mannose, UDP-N-acetylglucosamine, UDP-glucose, GDP-mannose, UDP-N-acetylgalactosamine, UDP-glucuronic acid, GDP-Fucose, and CMP-N-acetylneuraminic acid.
  • Donors include sugar derivatives that include active groups, such as cross-linking agents or labeling agents. Accordingly, oligosaccharides may be prepared according to the methods of the invention that include a sugar derivative having a desired characteristic.
  • “Expression cassette” as used herein means a DNA sequence capable of directing expression of a particular nucleotide sequence in an appropriate host cell, comprising a promoter operably linked to the nucleotide sequence of interest that is operably linked to termination signals. It also typically comprises sequences required for proper translation of the nucleotide sequence.
  • the expression cassette may be one that is naturally occurring but has been obtained in a recombinant form useful for heterologous expression.
  • the expression of the nucleotide sequence in the expression cassette may be under the control of a constitutive promoter or of an inducible promoter that initiates transcription only when the host cell is exposed to some particular external stimulus. In the case of a multicellular organism, the promoter can also be specific to a particular tissue or organ or stage of development.
  • oligosaccharide and polysaccharide are used interchangeably herein. These terms refer to saccharide chains having two or more linked sugars. Oligosaccharides and polysaccharides may be homopolymers and heteropolymers having a random sugar sequence or a preselected sugar sequence. Additionally, oligosaccharides and polysaccharides may contain sugars that are normally found in nature, derivatives of sugars, and mixed polymers thereof.
  • Polypeptides and Proteins are used interchangeably herein. Polypeptides and proteins can be expressed in vivo through use of prokaryotic or eukaryotic expression systems. Many such expressions systems are known in the art and are commercially available. (Clontech, Palo Alto, Calif.; Stratagene, La Jolla, Calif.). Examples of such systems include, but are not limited to, the T7-expression system in prokaryotes and the bacculovirus expression system in eukaryotes. Polypeptides can also be synthesized in vitro, e.g., by the solid phase peptide synthetic method or by in vitro transcription/translation systems. Such methods are described, for example, in U.S. Pat. Nos.
  • polypeptides can be further purified by fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on an anion-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; or ligand affinity chromatography.
  • polypeptides of the invention include polypeptides having amino acid exchanges, i.e., variant polypeptides, so long as the polypeptide variant is biologically active.
  • the variant polypeptides include the exchange of at least one amino acid residue in the polypeptide for another amino acid residue, including exchanges that utilize the D rather than L form, as well as other well known amino acid analogs, e.g., N-alkyl amino acids, lactic acid, and the like.
  • analogs include phosphoserine, phosphothreonine, phosphotyrosine, hydroxyproline, gamma-carboxyglutamate; hippuric acid, octahydroindole-2-carboxylic acid, statine, 1,2,3,4,-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, citruline, N-methyl-alanine, para-benzoyl-phenylalanine, phenylglycine, propargylglycine, sarcosine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, and other similar amino acids and imino acids and tert-butylglycine.
  • Conservative amino acid exchanges are preferred and include, for example; aspartic-glutamic as acidic amino acids; lysine/arginine/histidine as basic amino acids; leucine/isoleucine, methionine/valine, alanine/valine as hydrophobic amino acids; serine/glycine/alanine/threonine as hydrophilic amino acids.
  • Conservative amino acid exchange also includes groupings based on side chains. Members in each group can be exchanged with another. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine. These may be exchanged with one another.
  • a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine.
  • a group of amino acids having amide-containing side chains is asparagine and glutamine.
  • a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan.
  • a group of amino acids having basic side chains is lysine, arginine, and histidine.
  • a group of amino acids having sulfur-containing side chains is cysteine and methionine.
  • replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid may be accomplished to produce a variant polypeptide of the invention.
  • mutation of the donor binding site of ⁇ (1,4)-galactosyltransferase I can broaden the donor specificity of the enzyme. More specifically, it has been determined that substitution of amino acid residues located in the donor binding site of ⁇ (1,4)-galactosyltransferase I to provide greater flexibility and decreased steric hindrance allow glucose to be bound and chemically bonded to N-acetylglucosamine. Such mutations provide for broadened donor binding, such as binding of glucose, while still preserving interaction with amino acid residues active during catalytic bond formation between the donor and the acceptor.
  • an example of a catalytic residue thought to be important for catalysis is a glutamic acid positioned at amino acid position 317 (E317) in the bovine ⁇ (1,4)-galactosyltransferase I.
  • This glutamic acid in bovine ⁇ (1,4)-galactosyltransferase I corresponds to a glutamic acid residue at amino acid position 313 and at amino acid position 314 in the human and mouse ⁇ (1,4)-galactosyltransferase I respectively.
  • the invention provides ⁇ (1,4)-galactosyltransferase I mutants having amino acid substitutions, insertions, and deletions that provide greater flexibility and decreased steric hindrance in the donor binding site to allow the mutated ⁇ (1,4)-galactosyltransferase I to catalyze chemical bonding of the donor to an acceptor, such as N-acetylglucosamine or glucose.
  • the catalytic domains of the invention have an arginine exchanged with another amino acid at an amino acid position corresponding to 228 in the bovine ⁇ (1,4)-galactosyltransferase I (SEQ ID NO: 5).
  • An example of a specific exchange is R228K.
  • the corresponding arginine in the human and mouse ⁇ (1,4)-galactosyltransferase I is located at amino acid position 224 and 225 (SEQ ID Nos: 3 and 4 respectively).
  • the arginine is located within the amino acid sequence FNRAKLL (SEQ ID NO: 1). Accordingly, those of skill in the art can readily determine an equivalent amino acid in other ⁇ (1,4)-galactosyltransferase I catalytic domains.
  • the catalytic domains of the invention have an arginine exchanged with another amino acid at an amino acid position corresponding to 228, and an alanine exchanged with another amino acid at an amino acid position corresponding to 229 in the bovine ⁇ (1,4)-galactosyltransferase I.
  • Such catalytic domains are exemplified by a catalytic domain of bovine ⁇ (1,4)-galactosyltransferase I having the arginine at amino acid position 228 exchanged with lysine (R228K), and the alanine at amino acid position 229 exchanged with glycine (A229G).
  • the corresponding alanine in the human and mouse ⁇ (1,4)-galactosyltransferase I is located at amino acid position 225 and 226 (SEQ ID Nos: 3 and 4 respectively).
  • the arginine is located within the amino acid sequence FNRAKLL (SEQ ID NO: 1). Accordingly, those of skill in the art can readily determine an equivalent amino acid in other ⁇ (1,4)-galactosyltransferase I catalytic domains.
  • the invention includes mutants of ⁇ (1,4)-galactosyltransferase I in which hydrogen bonds that reduce transfer of N-acetylgalactosamine to an acceptor, such as N-acetylglucosamine or glucose, are reduced or absent.
  • the catalytic domains of the invention have a tyrosine exchanged with another amino acid at an amino acid position corresponding to 289 in the bovine ⁇ (1,4)-galactosyltransferase I (SEQ ID NO: 5).
  • Examples of specific exchanges are Y289L, Y289I, and Y289N.
  • the corresponding tyrosine in the human and mouse ⁇ (1,4)-galactosyltransferase I is located at amino acid position 285 and 286 (SEQ ID Nos: 3 and 4 respectively).
  • the tyrosine is located within the amino acid sequence YVQYFGG (SEQ ID NO: 2). Accordingly, those of skill in the art can readily determine equivalent amino acids in other ⁇ (1,4)-galactosyltransferase I catalytic domains.
  • Mutants in which the tyrosine corresponding to that located at amino acid position 289 in the bovine ⁇ (1,4)-galactosyltransferase I has been exchanged by another amino acid may optionally include a second mutation corresponding to amino acid position 342.
  • Such a mutation may include exchange of cysteine at amino acid position 342 with threonine (C342T).
  • C342T threonine
  • other amino acids may be exchanged for cysteine that provide and active catalytic domain.
  • ⁇ (1,4)-galactosyltransferase I mutants that are able to catalyze chemical bond formation of N-acetylgalactosamine to an acceptor may be used in conjunction with ⁇ -lactalbumin to catalyze the formation of N-acetylgalactosamine- ⁇ (1,4)-glucose bonds.
  • ⁇ -Lactalbumin is a mammary gland-specific calcium-binding protein that alters the sugar acceptor specificity of ⁇ (1,4)-galactosyltransferase I toward glucose. Consequently, ⁇ -lactalbumin may be used to alter the acceptor specificity ⁇ (1,4)-galactosyltransferase I, and mutants thereof that are described herein, to efficiently catalyze N-acetylgalactosamine- ⁇ (1,4)-glucose bond formation. Conditions for use of ⁇ -lactalbumin in conjunction with a galactosyltransferase, or active domain thereof, have been described (Ramakrishnan et al., J. Biol. Chem., 276:37665 (2001)).
  • catalytic domains having selectively altered donor specificities.
  • a catalytic domain obtained from bovine ⁇ (1,4)-galactosyltransferase I having exchanges at amino acid positions 228 (R228K) and 289 (Y289L) was able to catalyze the linkage of N-acetylglucosamine to N-acetylglucosamine to form a N-acetylglucosamine- ⁇ (1,4)-N-acetylglucosamine bond.
  • the same mutant catalytic domain was able to catalyze the linkage of N-acetylgalactosamine to N-acetylglucosamine to form oligo N-acetylgalactosamine- ⁇ (1,4)-N-acetylglucosamine.
  • the broadened donor specificity was further demonstrated by the ability of the mutant catalytic domain to catalyze the linkage of mannose to N-acetylglucosamine to form mannose- ⁇ (1,4)-N-acetylglucosamine.
  • mutant catalytic domains having altered donor specificity may be created by mutating amino acids corresponding to those at positions corresponding to 228 and 289 of the bovine ⁇ (1,4)-galactosyltransferase I. As described above, these amino acid positions may be readily determined in galactosyltransferase enzymes obtained from other organisms, such as humans, and mutated in produce additional catalytic domains having altered donor specificity.
  • the acceptor specificity of a catalytic domain obtained from a galactosyltransferase may be altered to create catalytic domains capable of transferring a donor onto an acceptor having a bulky and/or charged side-group.
  • An example of such an altered catalytic domain obtained from bovine ⁇ (1,4)-galactosyltransferase I has substitutions at amino acid positions 279 (K279S) and 280 (F280T).
  • This altered catalytic domain is able to catalyze the transfer of galactose to N-acetylglucosamine-6-SO 3 to form galactose- ⁇ (1,4)-N-acetylglucosamine-6-SO 3 .
  • Additional catalytic domains may be created by altering one or more amino acid residues at positions corresponding to 279 and 280 of the bovine ⁇ (1,4)-galactosyltransferase I. As described above, these amino acid positions may be readily determined in galactosyltransferase enzymes obtained from other organisms, such as humans, and mutated in produce additional catalytic domains having altered acceptor specificity.
  • the amino acids at positions corresponding to 279 and 280 in the bovine ⁇ (1,4)-galactosyltransferase I may be exchanged individually or together to create many different catalytic domains having altered acceptor sites able to accept numerous acceptors having bulky (sterically large) or charged side-groups. Such altered catalytic domains may be used to catalyze linkage of sugars from a donor to an acceptor having a desired side-chain.
  • Catalytic Domains of the Invention May be Included within Full-Length ⁇ (1.4)-galactosyltransferase I Enzymes, or in Recombinant Molecules Containing the Catalytic Domains.
  • Peptides of the invention include isolated catalytic domains, full-length ⁇ (1,4)-galactosyltransferase I enzymes containing a catalytic domain of the invention, as well as recombinant polypeptides comprising a catalytic domain of the invention that are linked to additional amino acids.
  • Such polypeptides may be expressed from DNA constructs and expression cassettes that are produced through use of recombinant methods. Such methods have been described. Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (2001).
  • Galactosyltransferase enzymes containing a catalytic domain of the invention may be produced in soluble form. Methods that may be used to produce such soluble enzymes have been described (U.S. Pat. No. 5,032,519). Briefly, a hydrophobic transmembrane anchor region of a galactosyltransferase is removed to produce an enzyme that is in soluble form.
  • ⁇ (1,4)-galactosyltransferase enzymes containing a catalytic domain of the invention may be produced such that they are anchored in the membrane of a cell that expresses the galactosyltransferase.
  • Such enzymes may be produced that are anchored in the membranes of prokaryotic and eukaryotic cells. Methods to produce such enzymes have been described (U.S. Pat. No. 6,284,493).
  • the signal and transmembrane sequences of the galactosyltransferase are replaced by a bacterial signal sequence, capable of effecting localization of the fusion protein to the outer membrane.
  • Suitable signal sequences include, but are not limited to those from the major E. coli lipoprotein Lpp and lam B.
  • membrane spanning regions from Omp A, Omp C, Omp F or Pho E can be used in a tripartite fusion protein to direct proper insertion of the fusion protein into the outer membrane.
  • Any procaryotic cells can be used in accordance with the present invention including but not limited to E. coli, Bacillus sp., and Pseudomonas sp. as representative examples.
  • the native transmembrane domain of the galactosyltransferase is replaced by the transmembrane domain of a bacterial outer membrane protein.
  • the galactosyltransferase signal sequence and the bacterial transmembrane region act in concert to anchor the galactosyltransferase to the bacterial outer cell membrane.
  • any outer membrane bound protein is suitable for this use including but not limited to Omp A, Omp C, and Omp F, Lpp, and Lam B.
  • the catalytic portion of the galactosyltransferase should be fused to an extracellular loop in the bacterial transmembrane region in order to insure proper orientation of the fusion protein on the outer membrane surface and not in the cytoplasm or periplasm of the cell. Insertion of a protein into such a loop region has been previously reported (Charbit et al., J. Bacteriology, 173:262 (1991); Francisco et al., Proc. Natl. Acad. Sci., 89:2713 (1992)).
  • the present invention is also applicable for use with eukaryotic cells resulting in cell surface expression of galactosyltransferases in known culturable eucaryotic cells including but not limited to yeast cells, insect cells, chinese hamster ovary cells (CHO cells), mouse L cells, mouse A9 cells, baby hamster kidney cells, C127 cells, COS cells, Sf9 cells, and PC8 cells.
  • yeast cells insect cells
  • chinese hamster ovary cells CHO cells
  • mouse L cells mouse L cells
  • mouse A9 cells mouse A9 cells
  • baby hamster kidney cells C127 cells
  • COS cells COS cells
  • Sf9 cells and PC8 cells.
  • the transmembrane domain of the galactosyltransferase is replaced by the transmembrane domain of a plasma membrane protein.
  • the transmembrane domain of any resident plasma membrane protein will be appropriate for this purpose.
  • the transmembrane portions of the M6 P/IGF-II receptor, LDL receptor or the transferrin receptor are representative examples.
  • the Golgi retention signal of the galactosyltransferase is disrupted by site-directed mutagenesis.
  • This approach mutates the amino acids responsible for localizing the galactosyltransferase to the Golgi compartment.
  • the resultant galactosyltransferase is transported to the plasma membrane where it becomes anchored via its modified transmembrane sequences.
  • Substitution of isoleucine residues for the native amino acids in the transmembrane region of the ⁇ (1,4)galactosyltransferase has been shown to preferentially localize the enzyme to the plasma membrane instead of the Golgi apparatus (Masibay et al., J. Biol. Chem., 268:9908 (1993)).
  • ⁇ (1,4)-galactosyltransferase I is a type II Golgi resident protein with a short cytoplasmic tail, a transmembrane domain followed by a stem region and has a globular catalytic domain that faces the Golgi lumen.
  • the catalytic domain of ⁇ (1,4)-galactosyltransferase I When expressed in E. coli , it forms insoluble inclusion bodies. These inclusion bodies can be collected and then solubilized and folded in vitro to produce catalytically active domains.
  • the in vitro folding efficiency is directly related to the quantity of active enzyme that is produced from the isolated inclusion bodies. Accordingly, methods to increase the in vitro folding efficiency would provide increased production of catalytic domains that can be used to create useful products.
  • the invention provides materials and methods that improve in vitro folding of catalytic domains from galactosyltransferases that are related to the use of a stem region (for example, SEQ ID NOs: 6 and 7) of ⁇ (1,4)-galactosyltransferase I. It has been determined that fusion of a stem region from a ⁇ (1,4)-galactosyltransferase I to the amino-terminus of the catalytic domain of a ⁇ (1,4)-galactosyltransferase I produces increased in vitro folding efficiency of the catalytic domain. This increase in folding is thought to be universal among ⁇ (1,4)-galactosyltransferase I enzymes and was demonstrated with both the bovine and human enzymes.
  • a stem region for example, SEQ ID NOs: 6 and 7
  • PEG-4000 and L-Arg are thought to beneficially affect the solubility of folding intermediates of both catalytic domain-proteins (CD-proteins) and stem region/catalytic domain proteins (SRCD-proteins) during in vitro folding or protein obtained from inclusion bodies.
  • CD-proteins catalytic domain-proteins
  • SRCD-proteins stem region/catalytic domain proteins
  • misfolded SRCD proteins in contrast to the majority of CD-proteins, remained soluble even in the absence of PEG-4000 and L-arginine. Therefore, the misfolded SRCD-proteins were not removed as precipitates during dialysis. Misfolded SRCD-proteins can be separated from properly folded proteins through binding on UDP-agarose columns (Table IX). Thus the SR-domain is thought to act as a solubilizing agent both for the misfolded and folded catalytic domain. It is thought that the increased solubility of SRCD-proteins is produced by preventing aggregation of misfolded proteins. In this respect its mode of action is thought to resemble the action of chaperone proteins. The positive effect of the N-terminal stem region in the folding and stability of the native protein is very useful for producing large quantities of other galactosyltransferase family members.
  • the in vitro folding efficiency of catalytic domains that include a stem region in the presence of PEG-4000 and L-Arg was about 50 percent and the solubility of the refolded product was about 90 percent.
  • the invention includes stem regions from members of the galactosyltransferase family that can be fused to a catalytic domain of a galactosyltransferase to provide increased in vitro folding of the catalytic domain.
  • stem regions can be readily determined based on amino acid sequence homology to the bovine stem region and tested for the ability to promote folding of a galactosyltransferase catalytic domain.
  • the invention also includes the mutants disclosed herein and their corresponding analogs in other species.
  • the present invention provides isolated nucleic acid segments that encode catalytic domains of ⁇ (1,4)-galactosyltransferase I having altered donor or acceptor specificity.
  • the present invention also provides nucleic acid segments that encode amino acid segments that promote proper folding of catalytic domains from galactosyltransferases, such as ⁇ (1,4)-galactosyltransferase I.
  • Nucleic acid sequences encoding human ⁇ (1,4)-galactosyltransferase I (SEQ ID NO: 8), as well as other ⁇ (1,4)-galactosyltransferases I from other organisms are available. These nucleic acid sequences can be modified to encode the catalytic domains and amino acid segments of the invention through use of well-known techniques (Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (2001)).
  • a portion of the nucleic acid sequence encoding human ⁇ (1,4)-galactosyltransferase I (SEQ ID NO: 8) can be inserted into an expression vector such that an amino acid segment corresponding to the catalytic domain of human ⁇ (1,4)-galactosyltransferase I (SEQ ID NO: 6) is expressed upon transformation of a cell with the expression vector.
  • bovine ⁇ (1,4)-galactosyltransferase I can be altered to replace the tyrosine at amino acid position 289 with leucine, isoleucine, or asparagine through use of site-directed mutagenesis (Ramakrishnan et al., J. Biol. Chem., 277:20833 (2002)). Similar methods may be used to produce nucleic acid segments encoding additional mutants and catalytic domains described herein.
  • nucleic acid segments of the invention may be optimized for expression in select cells. Codon optimization tables are available. Harlow and Lane, Antibodies: A Laboratory Manual , Cold Spring Harbor Laboratory Press, 1988.
  • the nucleic acid segments can be inserted into numerous types of vectors.
  • a vector may include, but is not limited to, any plasmid, phagemid, F-factor, virus, cosmid, or phage in double or single stranded linear or circular form which may or may not be self transmissible or mobilizable.
  • the vector can also transform a prokaryotic or eukaryotic host either by integration into the cellular genome or exist extrachromosomally (e.g. autonomous replicating plasmid with an origin of replication).
  • the nucleic acid segment in the vector is under the control of, and operably linked to, an appropriate promoter or other regulatory elements for transcription in vitro or in a host cell such as a eukaryotic cell or microbe, e.g. bacteria.
  • the vector may be a bi-functional expression vector which functions in multiple hosts. In the case of genomic DNA, this may contain its own promoter or other regulatory elements and in the case of cDNA this may be under the control of a promoter or other regulatory sequences for expression in a host cell.
  • shuttle vectors by which is meant a DNA vehicle capable, naturally or by design, of replication in two different host organisms, which may be selected from bacteria and eukaryotic cells (e.g. mammalian, yeast or fungal).
  • eukaryotic cells e.g. mammalian, yeast or fungal.
  • the vector may also be a cloning vector which typically contains one or a small number of restriction endonuclease recognition sites at which nucleic acid segments can be inserted in a determinable fashion. Such insertion can occur without loss of essential biological function of the cloning vector.
  • a cloning vector may also contain a marker gene that is suitable for use in the identification and selection of cells transformed with the cloning vector. Examples of marker genes are tetracycline resistance, hygromycin resistance or ampicillin resistance. Many cloning vectors are commercially available (Stratagene, New England Biolabs, Clonetech).
  • nucleic acid segments of the invention may also be inserted into an expression vector.
  • an expression vector contains (1) prokaryotic DNA elements coding for a bacterial replication origin and an antibiotic resistance gene to provide for the amplification and selection of the expression vector in a bacterial host; (2) regulatory elements that control initiation of transcription such as a promoter; and (3) DNA elements that control the processing of transcripts such as introns, transcription termination/polyadenylation sequence.
  • a vector into which the nucleic acid segment is to be inserted is treated with one or more restriction enzymes (restriction endonuclease) to produce a linearized vector having a blunt end, a “sticky” end with a 5′ or a 3′ overhang, or any combination of the above.
  • restriction enzymes restriction endonuclease
  • the vector may also be treated with a restriction enzyme and subsequently treated with another modifying enzyme, such as a polymerase, an exonuclease, a phosphatase or a kinase, to create a linearized vector that has characteristics useful for ligation of a nucleic acid segment into the vector.
  • the nucleic acid segment that is to be inserted into the vector is treated with one or more restriction enzymes to create a linearized segment having a blunt end, a “sticky” end with a 5′ or a 3′ overhang, or any combination of the above.
  • the nucleic acid segment may also be treated with a restriction enzyme and subsequently treated with another DNA modifying enzyme.
  • DNA modifying enzymes include, but are not limited to, polymerase, exonuclease, phosphatase or a kinase, to create a polynucleic acid segment that has characteristics useful for ligation of a nucleic acid segment into the vector.
  • the treated vector and nucleic acid segment are then ligated together to form a construct containing a nucleic acid segment according to methods known in the art (Sambrook, 2002). Briefly, the treated nucleic acid fragment and the treated vector are combined in the presence of a suitable buffer and ligase. The mixture is then incubated under appropriate conditions to allow the ligase to ligate the nucleic acid fragment into the vector. It is preferred that the nucleic acid fragment and the vector each have complimentary “sticky” ends to increase ligation efficiency, as opposed to blunt-end ligation. It is more preferred that the vector and nucleic acid fragment are each treated with two different restriction enzymes to produce two different complimentary “sticky” ends. This allows for directional ligation of the nucleic acid fragment into the vector, increases ligation efficiency and avoids ligation of the ends of the vector to reform the vector without the inserted nucleic acid fragment.
  • Suitable procaryotic vectors include but are not limited to pBR322, pMB9, pUC, lambda bacteriophage, m13 bacteriophage, and Bluescript®.
  • Suitable eukaryotic vectors include but are not limited to PMSG, pAV009/A+, PMTO10/A+, pMAM neo-5, bacculovirus, pDSVE, YIP5, YRP17, YEP. It will be clear to one of ordinary skill in the art which vector or promoter system should be used depending on which cell type is used for a host cell.
  • the invention also provides expression cassettes which contain a control sequence capable of directing expression of a particular nucleic acid segment of the invention either in vitro or in a host cell.
  • the expression cassette is an isolatable unit such that the expression cassette may be in linear form and functional in in vitro transcription and translation assays.
  • the materials and procedures to conduct these assays are commercially available from Promega Corp. (Madison, Wis.).
  • an in vitro transcript may be produced by placing a nucleic acid segment under the control of a T7 promoter and then using T7 RNA polymerase to produce an in vitro transcript. This transcript may then be translated in vitro through use of a rabbit reticulocyte lysate.
  • the expression cassette can be incorporated into a vector allowing for replication and amplification of the expression cassette within a host cell or also in vitro transcription and translation of a nucleic acid segment.
  • Such an expression cassette may contain one or a plurality of restriction sites allowing for placement of the nucleic acid segment under the regulation of a regulatory sequence.
  • the expression cassette can also contain a termination signal operably linked to the nucleic acid segment as well as regulatory sequences required for proper translation of the nucleic acid segment.
  • Expression of the nucleic acid segment in the expression cassette may be under the control of a constitutive promoter or an inducible promoter which initiates transcription only when the host cell is exposed to some particular external stimulus.
  • the expression cassette may include in the 5′-3′ direction of transcription, a transcriptional and translational initiation region, a nucleic acid segment and a transcriptional and translational termination region functional in vivo and/or in vitro.
  • the termination region may be native with the transcriptional initiation region, may be native with the nucleic acid segment, or may be derived from another source. Numerous termination regions are known in the art. Guerineau et al., Mol. Gen.
  • the regulatory sequence can be a nucleic acid sequence located upstream (5′ non-coding sequences), within, or downstream (3′ non-coding sequences) of a coding sequence, and which influences the transcription, RNA processing or stability, or translation of the associated coding sequence.
  • Regulatory sequences can include, but are not limited to, enhancers, promoters, repressor binding sites, translation leader sequences, introns, and polyadenylation signal sequences. They may include natural and synthetic sequences as well as sequences which may be a combination of synthetic and natural sequences. While regulatory sequences are not limited to promoters, some useful regulatory sequences include constitutive promoters, inducible promoters, regulated promoters, tissue-specific promoters, viral promoters and synthetic promoters.
  • a promoter is a nucleotide sequence that controls expression of the coding sequence by providing the recognition for RNA polymerase and other factors required for proper transcription.
  • a promoter includes a minimal promoter, consisting only of all basal elements needed for transcription initiation, such as a TATA-box and/or initiator that is a short DNA sequence comprised of a TATA-box and other sequences that serve to specify the site of transcription initiation, to which regulatory elements are added for control of expression.
  • a promoter may be inducible. Several inducible promoters have been reported ( Current Opinion in Biotechnology, 7:168 (1996)).
  • Examples include the tetracycline repressor system, Lac repressor system, copper-inducible systems, salicylate-inducible systems (such as the PR1a system). Also included are the benzene sulphonamide- (U.S. Pat. No. 5,364,780) and alcohol- (WO 97/06269 and WO 97/06268) inducible systems and glutathione S-transferase promoters. In the case of a multicellular organism, the promoter can also be specific to a particular tissue or organ or stage of development.
  • An enhancer is a DNA sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue specificity of a promoter. It is capable of operating in both orientations (normal or flipped), and is capable of functioning even when moved either upstream or downstream from the promoter. Both enhancers and other upstream promoter elements bind sequence-specific DNA-binding proteins that mediate their effects.
  • the expression cassette can contain a 5′ non-coding sequence which is a nucleotide sequence located 5′ (upstream) to the coding sequence. It is present in the fully processed mRNA upstream of the initiation codon and may affect processing of the primary transcript to mRNA, stability of the mRNA, or translation efficiency (Turner et al., Molecular Biotechnology, 3:225 (1995)).
  • the expression cassette may also contain a 3′ non-coding sequence which is a nucleotide sequence located 3′ (downstream) to a coding sequence and includes polyadenylation signal sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression.
  • the polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3′ end of the mRNA precursor.
  • the invention also provides a construct containing a vector and an expression cassette.
  • the vector may be selected from, but not limited to, any vector previously described. Into this vector may be inserted an expression cassette through methods known in the art and previously described (Sambrook et al., 1989).
  • the regulatory sequences of the expression cassette may be derived from a source other than the vector into which the expression cassette is inserted.
  • a construct containing a vector and an expression cassette is formed upon insertion of a nucleic acid segment of the invention into a vector that itself contains regulatory sequences.
  • an expression cassette is formed upon insertion of the nucleic acid segment into the vector.
  • Vectors containing regulatory sequences are available commercially and methods for their use are known in the art (Clonetech, Promega, Stratagene).
  • the expression cassette, or a vector construct containing the expression cassette may be inserted into a cell.
  • the expression cassette or vector construct may be carried episomally or integrated into the genome of the cell.
  • Transformation of bacteria and many eukaryotic cells may be accomplished through use of polyethylene glycol, calcium chloride, viral infection, phage infection, electroporation and other methods known in the art.
  • Other transformation methods are available to those skilled in the art, such as direct uptake of foreign DNA constructs (see EP 295959), techniques of electroporation (Fromm et al. Nature ( London ), 319:791 (1986) or high velocity ballistic bombardment with metal particles coated with the nucleic acid constructs (Kline et al. Nature ( London ) 327:70 (1987), and U.S. Pat. No. 4,945,050).
  • an expression vector contains (1) prokaryotic DNA elements coding for a bacterial origin of replication and an antibiotic resistance gene to provide for the amplification and selection of the expression vector in a bacterial host; (2) DNA elements that control initiation of transcription, such as a promoter; (3) DNA elements that control the processing of transcripts, such as introns, transcription termination/polyadenylation sequence; and (4) a reporter gene that is operatively linked to the DNA elements to control transcription initiation.
  • Useful reporter genes include ⁇ -galactosidase, chloramphenicol acetyl transferase, luciferase, green fluorescent protein (GFP) and the like.
  • Catalytic domains of the invention having altered donor and acceptor specificity can be used to catalyze the linkage of numerous sugars from a donor to numerous acceptor sugars. Linkage of sugar derivatives can also achieved through use of the altered catalytic domains of the invention due to their expanded donor and acceptor specificity.
  • the catalytic domains of section IA can be used to catalyze the linkage of glucose and N-acetylglucosamine; the catalytic domains of section IB can be used to catalyze the linkage of N-acetylgalactosamine and N-acetylglucosamine; many of the catalytic domains described herein can be used in association with ⁇ -lactalbumin to catalyze linkage of a sugar to glucose, as described in section IC; the catalytic domains of section ID can be used to catalyze the linkage of N-acetylglucosamine and N-acetylglucosamine, N-acetylgalactosamine to N-acetylglucosamine, and mannose to N-acetylglucosamine; and the catalytic domains of section IE can be used to catalyze the linkage of a donor and an acceptor having a bulky side-group, such as linking galactos
  • Acceptors may be free in solution or linked to another molecule.
  • an acceptor may be linked to a protein, another sugar, a sugar derivative, and the like.
  • An acceptor may also be linked to a solid support that provides a platform to which donors may be added sequentially to form oligosaccharides, and derivatives thereof, having a specified sequence.
  • the linkage between a donor and an acceptor is accomplished by incubating a catalytic domain of the invention with a desired donor and a desired acceptor under conditions of appropriate temperature, pH, and divalent metal concentration to allow linkage of the donor to the acceptor.
  • the galactose and N-acetylgalactosyltransferase activity of ⁇ (1,4)-galactosyltransferase I can be determined using the following assay conditions.
  • a 100 ⁇ l incubation mixture containing 50 mM ⁇ -benzyl-GlcNAc, 10 mM MnCl 2 , 10 mM Tris-HCl (pH 8.0), 500 ⁇ M UDP-Gal or UDP-GalNAc, and 20 ng of ⁇ (1,4)-galactosyltransferase I can be incubated at 37° C. for 10 minutes to promote coupling of a donor sugar to an acceptor sugar. While these conditions are provided as an example, it is understood that many other conditions may be used to chemically link a donor to an acceptor using the altered catalytic domains of the invention.
  • the invention provides methods to synthesize oligosaccharides, especially oligosaccharides having preselected sequences though use of the altered catalytic domains of the invention.
  • the methods involve the sequential addition of a sugar, or derivative thereof, to the end of a growing oligosaccharide chain.
  • Such methods have been described using enzymes other than those of the invention (U.S. Pat. No. 6,284,493).
  • a donor and an acceptor may be incubated with an altered catalytic domain of the invention under conditions that allow the donor to be linked to the acceptor. These conditions are described in the examples section herein.
  • the donor and the acceptor may be combined with a catalytic domain of the invention in solution.
  • the solution is then incubated to allow the donor to be linked to the acceptor.
  • the newly linked molecule may be isolated and then added to a second solution containing a second donor and a second transferase enzyme. This cycle may be repeated with a specific donor added at each cycle such that an oligosaccharide having a specific sequence is produced.
  • an acceptor may be linked to a solid support.
  • the solid support may then be immobilized in a structure such as a column or a tray.
  • a donor and a catalytic domain of the invention can then be incubated with the immobilized acceptor under conditions that allow the donor to be linked to the acceptor.
  • the solid support is then washed to remove any unlinked donor and catalytic domain present.
  • a second donor and a second transferase enzyme can then be added and incubated under conditions that allow the donor to be linked to the acceptor. This cycle can be repeated to allow for the rapid and large-scale production of oligosaccharides having defined sequences.
  • this method may be readily adapted for use in an automated system.
  • This system may be used without the need for protecting groups on the acceptor or the donor due to the use of enzymes that catalyze the linkage of a given donor to a given acceptor. Accordingly, an advantage of this method is that mild reaction conditions may be used that do not damage the growing oligosaccharide chain. Another advantage of the method is the short cycling time required to add monomers onto the growing oligosaccharide chain due to the lack of a need to protect and deprotect the growing oligosaccharide chain.
  • the invention provides methods to increase the immunogenicity of an antigen. Generally, the methods involve incubating an antigen with a catalytic domain of the invention such that a sugar is transferred from a donor to an acceptor through the action of a catalytic domain.
  • the methods of the invention may be used in association with nearly any acceptor containing material against which an immune response is desired.
  • sugars may be transferred from a donor to an acceptor that is linked to a whole cell.
  • the cell can then be killed through irradiation or chemical means and administered to an animal to elicit an immune response.
  • Cell membranes may be used in a similar manner. Methods to create an immune response against cells and cell membranes are described in U.S. Pat. No. 6,361,775.
  • the immunogenicity of a virus or subunit thereof may be increased according to the methods of the invention and used as an improved vaccine.
  • a virus that contains a glycoprotein as a component of the virion one or more sugars may be added to the glycoprotein by propagation of the virus in a cell that expresses a catalytic domain of the invention.
  • one or more sugars may be directly added to the glycoprotein using a catalytic domain of the invention.
  • viruses without envelopes that contain complex carbohydrates may be added onto these carbohydrates through use of a catalytic domain of the invention.
  • Viral subunits may be obtained from virions using biochemical methods or they can be expressed by recombinant means in suitable eukaryotic cells. Methods of expressing viral subunits are common in the art. These methods may vary according to the type of virus used. For example, methods of expressing viral subunits are described in the following articles and in the references cited therein: Possee, Virus Research. 5:43 (1986); Kuroda et al., EMBO J., 5: 1359 (1986); Doerfler, Curr. Topics Microbiol. Immunol., 131:51 (1986); Rigby, J. Gen. Virol. 64:255 (1983); Mackett et al., In: DNA Cloning, A Practical Approach, Vol II, Ed.
  • Viruses for which vaccines are currently available and whose immunogenicity can be improved according to the methods of the invention include influenza virus (Orthomyxovirus); rabies virus (Rhabdovirus); hepatitis B virus (Hepadnavirus); eastern, western and Venezuelan equine encephalitis virus (Togavirus/Alphavirus genus); and, Japanese encephalitis virus, tick-borne encephalitis virus and Russian spring-summer encephalitis virus (Flavivirus); Rift Valley fever virus (Bunyavirus) (reviewed: Melnick, In: High Technology Route to Virus Vaccines Ed. Dreesman, Bronson and Kennedy, American Society for Microbiology, Washington, D.C.
  • Viruses for which vaccines are not yet commercially available but which may also be useful when treated according to the methods of the invention include, but are not limited to human immunodeficiency and human T-cell leukemia viruses (Retrovirus); respiratory syncytial virus and other paramyxoviruses (Paramyxovirus); herpes simplex viruses types 1 and 2, varicella zoster virus, cytomegalovirus and other herpes viruses (Herpesviruses); dengue virus and Saint Louis encephalitis virus (Flavivirus); hantaan virus (Bunyavirus); Lassa virus (Arenavirus); and, rotavirus (Reovirus).
  • Rovirus human immunodeficiency and human T-cell leukemia viruses
  • Paramyxovirus paramyxovirus
  • vaccines comprising live attenuated viruses the administration of which to humans is associated with some measure of risk of mild to severe side effects. It is now possible according to the methods of the invention to enhance the immunogenicity of killed virus vaccines which may serve to reduce the use of their live, more risk-associated counterparts.
  • vaccines which currently comprise live virus such as measles virus, mumps virus, rubellavirus etc. are all encompassed by the invention.
  • Vaccines are prepared by suspension of a suitable concentration of an antigen that has been linked to a sugar, through the action of a catalytic domain of the invention, in a pharmaceutically acceptable carrier.
  • the composition of the carrier will depend upon the type of vaccine and the route of administration and will be readily apparent to one skilled in the art.
  • the vaccine may be administered in a dose of 10 2 to 10 9 cells per dose (in the case of whole cells) or a similar equivalent of cell membranes.
  • virus may be administered in dose ranging from 1 ⁇ g to 50 mg of virus per dose, or a similar equivalent of subunit. Determination of the appropriate dosage of vaccine will be apparent to one of skill in the art and will depend upon the antigens comprising the vaccine, the age of the patient and their general and immunological health.
  • patients may be pretreated with adjuvant at the site of vaccination several days prior to administration of vaccine.
  • Pretreatment with adjuvant serves to induce migration of macrophages to the site of inoculation, thereby enhancing the rate of phagocytosis of treated antigens.
  • patients may be treated with adjuvant and vaccine simultaneously.
  • Adjuvants suitable for this purpose include aluminum hydroxide and like adjuvants.
  • Vaccines are administered to a mammal, particularly a human, either subcutaneously, intramuscularly, orally, intravenously, intradermally, intranasally or intravaginally.
  • the vaccine Prior to oral administration, can be mixed with a solution containing a sufficient amount of sodium bicarbonate or other suitable compound capable of neutralizing stomach acid (approximately 2 grams).
  • the vaccine usually in lyophilized form, can be formulated as tablets which are treated with a coating capable of resisting stomach acid.
  • Bacterial growth and plasmid transformations were performed using standard procedures (Ausubel et al., Current Protocols in Molecular Biology , Greene Publishing Associates and Wiley-Interscience, New York (1987)).
  • the plasmid pEGT-d129 which encodes the catalytic domain (residues 130-402) of bovine ⁇ (1,4)-galactosyltransferase I, was used for mutation.
  • Site-directed mutagenesis was performed using a CLONTECH site-directed mutagenesis transformer kit.
  • the transformation mixture contained the template pEGT-d129, a selection primer, and a mutagenic primer for creation of a desired mutant.
  • Mutants were screened for the incorporated mutations by looking for changes in restriction enzyme digestion patterns and confirmed by DNA sequencing.
  • the positive clones were transformed into B834(DE3)pLysS cells.
  • the primers were synthesized by the Molecular Technology Laboratory, NCI-Frederick.
  • inclusion bodies were carried out as described previously (Ausubel et al., Current Protocols in Molecular Biology , Greene Publishing Associates and Wiley-Interscience, New York (1987)).
  • the inclusion bodies were S-sulfonated by dissolving in 5 M GdnHCl, 0.3 M sodium sulfite, and the addition of di-sodium 2-nitro-5-thiosulfobenzoate to a final concentration of 5 mM.
  • the sulfonated protein was precipitated by dilution with water, and the precipitate was washed thoroughly.
  • the sulfonated protein was re-dissolved in 5 M GdnHCl to a protein concentration of 1 mg/ml (1.9-2.0 optical density at 275 nm).
  • the protein solution was diluted 10-fold, in 10 portions, in a folding solution to give a final concentration of 100 ⁇ g/ml ⁇ (1,4)-galactosyltransferase I, 0.5 M GdnHCl, 50 mM Tris-HCl, 5 mM EDTA, 4 mM cysteamine, and 2 mM cystamine, pH 8.0 at 4° C. It was left at 4° C.
  • Site-directed Mutagenesis of amino acid position 289 of the bovine ⁇ (1,4)-galactosyltransferase I Site-directed mutagenesis was performed using the PCR method. Construction of the mutants was done using plasmid pEGT-d129 as the template; this contains a BamH1/EcoRI fragment inserted into pEGT23a vector, coding for the residues 130-402 of bovine ⁇ (1,4)-galactosyltransferase I, and has a Cys-342 to Thr mutation.
  • the mutation primers corresponding to the upper DNA strand are: Y289L, 5′-CCTTACGTGCAATTGTTTGGAGGTGTCTCTGCTCTAAGTAAA-3′ (SEQ ID NO: 11) and 5′-GACACCTCCAAACAATTGCACGTAAGGTAGGCTAAA-3′ (SEQ ID NO: 12); Y289I, 5′-CTACCTTACGTGCAGATCTTTGGAGGTGTCTCTGCTCTAAG-3′ (SEQ ID NO: 13) and 5′-GACACCTCCAAAGATCTGCACGTAAGGTAGGCTAATCCAA-3′ (SEQ ID NO: 14); Y289N, 5′-GGATTAGCCTACCATATGTGCAGAATTFTGGAGGTGTCTCT-3′ (SEQ ID NO: 15) and 5′-AGAGACACCTCCAAAATTCTGCACATCTGGTAGGCTAAATCC-3′ (SEQ ID NO: 16).
  • the entire Gal-T1 DNA was PCR-amplified as two fragments using the terminal cloning primers and two mutagenesis primers. The fragments were then cut with the restriction enzymes MfeI, BglII, and NdeI for Y289L, Y286I, and Y286N mutants, respectively, and ligated.
  • the full Gal-T1 DNA with the mutation was amplified from the ligation mixture using the cloning primers and then inserted into the pET28a vector. Mutants were screened for the incorporated mutations, based on alterations in the restriction enzyme digestion patterns, and then sequenced.
  • the positive clones were transformed into B834(DES)pLys8 cells as described previously (Ramakrishnan et al., J. Biol. Chem., 270, 87665-376717 (2001)).
  • the mutant proteins were expressed and purified according to the published method (Ramakrishnan et al., J. Biol. Chem., 270, 87665-376717 (2001)).
  • Gal-T and GalNAc-T Enzyme Assays The protein concentrations were measured using the Bio-Rad protein assay kit, based on the method of Bradford and further verified on SDS gel. An in vitro assay procedure for the Gal-T1 has been reported previously (Ramakrishnan et al., J. Biol. Chem., 270, 87665-376717 (2001)). The activities were measured using UDP-Gal or UDP-GalNAc as sugar nucleotide donors, and GlcNAc and Glc as the acceptor sugars.
  • the reaction was terminated by adding 200 ⁇ l of cold 50 mM EDTA, and the mixture was passed through a 0.5-ml bed volume column of AG1-X8 cation resin (Bio-Rad) to remove any unreacted [ 3 H]UDP-Gal or [ 3 H]UDP-GalNAc.
  • the column was washed successfully with 300, 400, and 500 ⁇ l of water, and the column flow-through was diluted with Biosafe scintillation fluid; radioactivity was measured with a Beckman counter. A reaction without the acceptor sugar was used as a control.
  • a similar assay was carried out to measure the GalNAc-T activity with Glc and other acceptors in the presence of 50 ⁇ M bovine LA (Sigma).
  • K A and of the acceptor (K B ), the dissociation constant of the donor, K i(a) , and k cat were obtained using two-substrate analyses and the primary plots of five concentrations of donor (UDP-Gal or UDP-GalNAc) and five concentrations of acceptor, and the corresponding secondary plots of the intercepts and slopes. Initial rate conditions were linear with respect to time. A suitable range of donor and acceptor concentrations were chosen, which allowed an accurate Michaelis-Menten plot to be derived.
  • Equation 2 is for asymmetric initial velocity pattern for a double displacement or “ping-pong” mechanism.
  • the kinetic parameters K A , K B , K i(a) , and V max were obtained from the fitted curves using the above rate equations.
  • the graphical method and EnzFitter program gave very similar kinetic parameters.
  • GalNAc-T N-acetylgalactosamine transferase
  • the maximum substrate concentrations used for UDP-GalNAc and GlcNAc were 1 and 200 mm, respectively.
  • the concentration of GlcNAc was limited to no more than 400 mM (which is 2-fold higher than its K m value), whereas up to 300 ⁇ M UDP-Gal were used.
  • the mutants Y289L, Y289N, and Y289I exhibited both galactose transferase and N-acetylgalactosyltransferase activities (Table III and FIG. 1 ).
  • the mutants Y289L and Y289N exhibited equally strong galactose transferase and N-acetylgalactosyltransferase activities.
  • the specific N-acetylgalactosyltransferase activity of the mutant Y289I at the substrate concentration used was half that of Y289L (Table III).
  • the Y289I mutant exhibited a slightly weaker affinity to UDP-GalNAc ( FIG. 1 ).
  • the Asn substitution exhibited GalNAc-T activity as well as the Leu substitution.
  • Wild-type-Gal-T1 exhibits a very low glucosyltranferase activity, but no N-acetylglucosaminyltransferase activity (Berliner and Robinson, Biochemistry, 21:6840-68433 (1982); Palmin and Hindaganl, Glycobiology, 1:205-209 (1991); Ramakrishnan et al., J. Biol. Chem., 270:87665-37671 (2001)).
  • the mutants exhibited reasonable N-acetylglucosaminyltransferase activity (Table III) where they transfer N-acetylglucosamine from UDP-N-acetylglucosamine to the acceptor N-acetylglucosamine but do not exhibit glucosyltranferase activity.
  • N-acetylglucosaminyltransferase activity the initial product, the disaccharide GlcNAc ⁇ 1,4-GlcNAc, itself is an acceptor for the enzyme, thus producing tri- and longer chain saccharides.
  • the concentration for the donors was 500 ⁇ M and the acceptor ⁇ -benzyl-GlcNAc was 25 mM.
  • the acceptor concentration was 10 mM, because at 25 mM it showed inhibition. Because Y289N rapidly undergoes denaturization, reliable data could not be obtained.
  • the Y289L mutant exhibits equally high GalNAc-T activity as it does Gal-T activity, the disaccharide product from this reaction was purified and analyzed by 1 H NMR spectroscopy ( FIG. 4 ). The NMR results demonstrated that the mutant Y289L transfers GalNAc from UDP-GalNAc to GlcNAc, forming ⁇ 1-4 linkage between GalNAc and GlcNAc.
  • a Point Mutation in the Codon for Amino Acid 289 Can Convert the Enzyme with Dual Property:
  • the ⁇ 4Gal-T family has seven members (Gal-T1 to -T7), each with high sequence identity within their catalytic domain (Lo et al., Glycobiology, 8:517-526 (1998); Nomura et al., J. Biol. Chem., 273:13570-13577 (1998)).
  • These family members transfer Gal from UDP-Gal to different sugar acceptors.
  • Gal-T6 transfers Gal to Glc of Glc-ceramide
  • Gal-T7 transfers Gal to xylose (Nomura et al., J. Biol. Chem.
  • Gal-T1 to Gal-T4 have a Tyr residue at position 287 (which corresponds to Tyr-289 in bovine Gal-T1), whereas Gal-T5 and Gal-T6 have a Phe residue.
  • LA ⁇ -Lactalbumin
  • LA plays a kinetics role in stimulating Gal-T1 to transfer Glc from the UDP-Glc to GlcNAc (Ramakrishnan et al., J. Biol. Chem., 270:87665-37671 (2001); Ramakrishnan et al., Biochem Biophys. Res. Commun., 291:1113-1118 (2002)).
  • the activity is enhanced by approximately 1%. This level of activity was determined using the donor concentration of the unlabeled UDP-sugar, and only a small amount of 3 H-labeled UDP-sugar. Use of this protocol allowed for accurate calculation based on the amount of unlabeled UDP-sugar used.
  • the Tyr-289 mutants (Y289L, Y289N, and Y289I) in the presence of LA transfer GalNAc preferably to Glc rather than to GlcNAc.
  • This property is quite similar to LS activity in which the wt-Gal-T1 in the presence of LA transfers Gal to Glc instead to GlcNAc (Table VI).
  • these mutants also transfer Gal to Glc in the presence of LA.
  • N-acetylgalactosaminyltransferase activity in the bovine mammary gland extracts with a similar catalytic property has been identified (Van den Nieuwenhof et al., FEBS Lett., 459:377-380 (1999)).
  • This enzyme also transfers GalNAc from UDP-GalNAc to GlcNAc in the absence of LA, whereas in the presence of LA it transfers GalNAc to Glc instead to GlcNAc.
  • the Tyr-289 mutants of Gal-T1 exhibit as high GalNAc-T activity as Gal-T activity, as well as GlcNAc-T activity.
  • the Tyr/Phe residue at 287 (or in bovine Tyr-289) is important for determining the donor sugar specificity of the enzyme.
  • oligonucleotide primers with unique restriction sites added at the 5′ (SR) and 3′ (CD) ends were synthesized based upon the bovine ⁇ 4Gal-T1 and human ⁇ 4Gal-T1 cDNA sequence (shown in FIGS. 3A and 3B ).
  • a full-length bovine cDNA clone encoding ⁇ 4Gal-T1 was used for site-directed mutagenesis (Boeggeman et al., Protein Eng. 6:779-785 (1993)).
  • bovine ⁇ 4Gal-T1 Ser96 was mutated to Ala96 (described below).
  • the mutated full-length cDNA template was amplified by the polymerase chain reaction (PCR), using the following primer pair to generate SRCD ⁇ 4Gal-T1:
  • SEQ ID NO: 19 (SR) 5′-CGC GGATCC CGCGACCTGAGCCGCCTGCCCCAACTGGTC-3′ and (SEQ ID NO: 20) (CD) 5′-CCG GAATTC CTACTAGCTCGGTGTCCCGATGTCCACTGT- 3′.
  • the primer pairs amplified the cDNA region that has both the stem and catalytic domain, and were designed to generate DNA fragments containing a Bam HI (SR) and Eco RI (CD) (underlined) at the 5′ and 3′-ends of the inserts, respectively.
  • the PCR products were purified using a QLAquick PCR purification kit and the purified fragments were digested with Bam HI and Eco RI to generate the cohesive ends.
  • the expression constructs were obtained after ligating the digested and gel-purified PCR fragments into the Bam HI and Eco RI-digested pET23a vector (Novagen, Madison, Wis.) and transformed into XL2-ultracompetent cells. Identities of the clones were confirmed by DNA sequence.
  • the wild-type bovine SRCD ⁇ 4Gal-T1 which has Ser at position 96, was expressed in E. coli . Its sequence is shown in FIG. 3A .
  • the cleaved protein on SDS-PAGE shows a single band of molecular mass of 34.9 kDa.
  • the protein was electroblotted to polyvinylidene difluoride membrane, and the N-terminal sequence of the cleaved fragment was determined by Edman degradation at the Protein Chemistry Laboratory, NCI-Frederick.
  • the N-terminal sequence of the fragment was determined as SRAPSNLD (SEQ ID NO: 21). This corresponds to the cleavage at Ser96 within the sequence region KPR 96 SRAPSNLD (SEQ ID NO: 22).
  • SRAPSNLD SEQ ID NO: 21
  • KPR 96 SRAPSNLD SEQ ID NO: 22
  • bovine SRCD ⁇ 4Gal-T1 the mutant bovine S96A-SRCD ⁇ 4Gal-T1 ( FIG. 3A ), for the sake of convenience in abbreviation this protein is simply referred to as bovine SRCD ⁇ 4Gal-T1.
  • the human SRCD ⁇ 4Gal-T1 also gets cleaved within the stem region, at Val53 in the sequence QLV 53 GVSTPLQ (SEQ ID NO: 23), but only after long periods of time. Since this clone showed more stability than the bovine ⁇ 4Gal-T1, it was not mutated and used as such for subsequent analysis.
  • Protein expression in E. coli and inclusion body isolation For protein expression BL21 ( ⁇ DE3)/pLysS-competent cells were transformed with the pET vector derivatives according to the manufacturer's protocols. The transformed cells were grown in LB broth containing 50 ⁇ g.ml ⁇ 1 ampicillin to an OD600 nm of ⁇ 0.7, followed by induction with 0.4 mM IPTG. Cultures were harvested after 3-4 hours by centrifugation at 2000 ⁇ g for 20 min. The inclusion bodies were isolated and solubilized as described (Boeggeman et al., Protein Eng., 6:779-785 (1993)). From a liter of induced bacterial culture, the yield is generally 80 to 100 mg of purified inclusion bodies. Novex gels were used for SDS-PAGE analysis and the protein bands were visualized with Coomassie blue. Protein concentrations were measured with the Bio-Rad protein dye reagent with bovine serum albumin as the standard.
  • the sulphonated proteins were dissolved in 5 M guanidine-HCl, to a protein concentration of 1 mg/ml, with an OD275 nm of 1.9 to 2.0.
  • the protein solution was then diluted 10-fold in small aliquots in a renaturation solution to give a final protein concentration of 100 ⁇ g/ml, in 50 mM Tris-HCl pH 8.0, 5 mM EDTA, 0.5 M guanidine-HCl, 8 mM cysteamine and 4 mM cystamine.
  • the protein was allowed to renature for 48 hrs at 4° C. and then dialyzed. The precipitate was removed by centrifugation at 5000 rpm and the supernatant concentrated using ultrafiltration membranes (Amicon, Inc., Beverly, Mass., USA).
  • Condition I 50 mM Tris-HCl pH 8.0, 5 mM EDTA, 0.5 M guanidine-HCl, 8 mM cysteamine and 4 mM cystamine.
  • Condition II 55 Mes pH 6.5, 10.56 mM NaCl, 0.44 mM KCl, 2.2 mM MgCl 2 , 2.2 mM CaCl 2 , 0.5 M guanidine-HCl.
  • Condition III similar to condition II with respect to the buffer, pH, chaotrope and salt condition, but it had 0.055% PEG-4000, 1.1 mM EDTA, 0.44 M sucrose and 0.55 M L-arginine.
  • Condition IV 55 mM Mes pH 6.5, 264 mM NaCl, 11 mM KCl, 0.055% PEG-4000, 0.5 M guanidine-HCl, 2.2 mM MgCl 2 , 2.2 mM CaCl 2 and 0.44 M sucrose.
  • Condition V 55 mM Tris pH 8.2, 10.56 mM NaCl, 0.44 mM KCl, 1.1 mM EDTA, 0.44 M sucrose.
  • Conditions VI and VIII are similar except for the presence of redox agents.
  • Condition VII 55 mM Mes pH 6.5, 264 mM NaCl, 11 mM KCl, 1.1 mM EDTA, 0.5 M guanidine-HCl, and 0.55 M L-arginine.
  • the buffers II through VII had 100 mM GSH and 10 mM GSSG.
  • Conditions I and VIII, had 8 mM cysteamine and 4 mM cystamine.
  • Condition VIII gave the highest enzymatic activity, soluble and folded protein, was 50 mM Tris-HCl pH 8.0, 10.56 mM NaCl, 0.44 mM KCl, 2.2 mM MgCl 2 , 2.2 mM CaCl 2 0.5 M guanidine-HCl, 8 mM cysteamine and 4 mM cystamine, 0.055% PEG-4000 and 0.55 M L-arginine.
  • ⁇ 4Gal-T1 Enzyme Assays The in vitro assay for ⁇ 4Gal-T1 enzyme activity was performed as described (Boeggeman et al., Glycobiology, 12:395-407 (2002)). The 3 H-labeled-UDP-Gal was used as sugar donor and GlcNAc as the sugar acceptor. A reaction without GlcNAc was used as a control. The fusion SRCD ⁇ 4Gal-T1 proteins showed the same enzymatic activities when compared to the wild-type recombinant ⁇ 4Gal-T1 (amount of product formation/min/mol of protein).
  • UDP-agarose was used to bind the active proteins at 4° C. Columns containing 1 ml bed volume of UDP-agarose were pre-equilibrated with 10 ml of 25 mM cacodylic buffer, pH 7.6, containing 25 mM MnCl 2 . The renatured protein solutions (0.5 mg) were adjusted to the pre-equilibration buffer conditions and applied to the columns. After loading the sample, the pass-through was re-cycled. It was then analyzed for the unbound protein by SDS-PAGE. The columns were washed 3 ⁇ with 1-ml portions of equilibration buffer.
  • the bound protein was eluted with the elution buffer consisting of 25 mM cacodylic buffer, pH 7.6, 25 mM EDTA and 1 M NaCl. Fractions of 0.5 ml were collected from the columns, and aliquots were analysed by SDS-PAGE. For enzymatic analysis the appropriate fractions were pooled and dialysed against 50 mM Tris-HCl pH 8.0 at 4° C.
  • Circular dichroism-spectroscopy Far ultraviolet circular dichroism spectra of recombinant proteins was measured in a JASCO J-715 spectropolarimeter. The spectra for each sample was scanned at a speed of 100 nm/min. Far ultraviolet circular dichroism spectra were obtained from 190 to 250 nm at room temperature using a pathlength of 0.1 mm with a 1.0 nm bandwidth. Protein was dissolved in Tris-HCl pH 8.0 at concentrations of 0.5 mg/ml. Buffer blanks obtained in the same cuvette were subtracted to generate net spectra. Raw ellipticity data were transformed into molar residue ellipticity using the concentration values determined from optical ultraviolet absorbance measurements. No smoothing or data averaging was applied.
  • the catalytic domain of ⁇ 4Gal-T1 (amino acid residues 130-402) (sequence in FIG. 3A , SEQ ID NO: 9) accumulated as an insoluble material within the inclusion body fraction upon expression in E. coli .
  • Essentially all the proteins with the stem regions covalently linked to the N-termini of the catalytic domain also accumulated in the insoluble inclusion body fraction.
  • Contaminating proteins from the inclusion bodies were removed by washing the insoluble pellet several times with a buffer containing 25% sucrose as described herein.
  • the yield of the purified inclusion bodies varied with the protein that is being expressed (Table VII).
  • the proteins produced a single protein band of expected molecular size on SDS-PAGE gel ( FIG. 4 ). These insoluble inclusion bodies required 5 M guanidine HCl for solubilization.
  • the proteins after the renaturation step were dialyzed, centrifuged and their concentration determined by SDS-PAGE and the Bradford method (BioRad) *Percentage recovery of the soluble protein after in vitro folding of 20 mg of sulphonated ⁇ 4Gal-T1 ⁇ circumflex over ( ) ⁇
  • the soluble renatured CD ⁇ 4Gal-T1 protein contains almost all folded molecules, whereas the soluble renatured SRCD ⁇ 4Gal-T1 contains misfolded proteins that are removed on UDP-agarose columns (see Table IX)
  • Renaturation conditions that increase the folding efficiency and specific activity of ⁇ 4Gal-T1 After folding the bovine wild-type CD ⁇ 4Gal-T1 in a renaturation buffer I (described herein), the misfolded proteins precipitated out during subsequent dialysis. In an attempt to increase the amount of the folded native protein during the renaturation step, various folding conditions consisting of seven different solutions were tested. The results were compared to the yields obtained according to condition I ( FIG. 5 ). The tested inclusion bodies were dissolved in 5 M guanidine HCl to a final protein concentration of 1 mg/ml.
  • the folding buffers varied, (conditions I to VIII as disclosed herein) with respect to: pH from 6.5 (in conditions II, III, IV and VII), to 8.0 (in conditions V, VI, and VIII); cations (in conditions II, IV, VI and VIII) and chelators (conditions I, III, V and VII).
  • Conditions VI, VII and VIII had polar additives (L-arginine).
  • Conditions IV and V had non-polar additives, such as sucrose.
  • Condition III had both sucrose and L-arginine.
  • Misfolded proteins in the renatured SRCD ⁇ Gal-T1 Renatured proteins were analyzed on SDS-PAGE gels under native and reducing conditions to determine whether the renatured SRCD ⁇ 4Gal-T1 proteins were natively folded or misfolded. Analyses under native conditions, in the absence of ⁇ -mercaptoethanol ( ⁇ ME) and without boiling the samples, revealed that both bovine and human soluble SRCD ⁇ 4Gal-T1 proteins contained misfolded molecules that aggregated and remained at the top of the gel ( FIG. 6 ( ⁇ )).
  • ⁇ ME ⁇ -mercaptoethanol
  • Binding of recombinant proteins to affinity columns Folded and active CD ⁇ 4Gal-T1 obtained from inclusion bodies bound to, and was eluted from, a UDP-column with 25 mM EDTA and 1M NaCl. Thus, binding of soluble renatured CD and SRCD ⁇ 4Gal-T1 proteins to UDP-agarose columns was tested. Native SDS gel analyses of the soluble renatured CD ⁇ 4Gal-T1 protein, without ⁇ ME and boiling, showed that all of the soluble renatured CD protein was natively folded. The renatured SRCD ⁇ 4Gal-T1 proteins were then applied to a UDP-agarose column.
  • FIG. 8A (+) had 2- and 6-fold higher specific activities ( FIG. 8A , crossed-hatched bars), respectively, when compared to the protein before loading onto the affinity column ( FIG. 8A , black bars).
  • the renatured human SRCD ⁇ 4Gal-T1 sample showed more misfolded proteins compared to bovine SRCD ⁇ 4Gal-T1 ( FIG. 8A , bovine versus human black bars).
  • folding according to condition VIII that contains PEG-4000 and L-arginine
  • FIG. 8B increased properly folded human SRCD compared to condition I ( FIG. 8B vs FIG. 8A , black bars, human SRCD). Protein eluted from the UDP-column under condition VIII ( FIG.
  • Circular dichroism-spectra of recombinant ⁇ 4Gal-T1 Circular dichroism experiments were done with purified ⁇ 4Gal-T1 proteins to determine if the addition of the stem disturbed the overall secondary structure of ⁇ 4Gal-T1. No significant differences in secondary structure relative to the wild-type CD ⁇ 4Gal-T1 were detected for the bovine or human proteins. All systems showed extrema of negative ellipticity between 250 and 200 nm. The circular dichroism-spectrum of the wild-type enzyme was highly reproducible and showed negative extrema at 208 and 220 nm indicative of ⁇ -helicity. There was a small change in ellipticity observed in the 200-210 nm region upon the addition of the stem in both bovine and human SRCD proteins.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed are methods and compositions that can be used to synthesize oligosaccharides; mutants of galactosyltransferases having altered donor and acceptor specificity; methods for increasing the immunogenicity of an antigen; and polypeptide stem regions that can be used to promote in vitro folding of polypeptides, such as the catalytic domain from a galactosyltransferase.

Description

    PRIORITY OF INVENTION
  • This application is a divisional application of U.S. patent application Ser. No. 11/178,230, filed Jul. 8, 2005, which is a continuation under 35 U.S.C. 111(a) of International Application No. PCT/US2004/000470 filed Jan. 9, 2004, and published in English as WO 2004/063344 on Jul. 29, 2004, which claims priority from U.S. Provisional Application No. 60/439,298, filed 10 Jan. 2003, and U.S. Provisional Application No. 60/450,250, filed 25 Feb. 2003, which are incorporated herein by reference.
    • GOVERNMENT FUNDING
  • The invention described herein was developed with support from the National Institutes of Health, under contract NO1-CO-12400. The U.S. Government may have certain rights in the invention.
    • FIELD OF THE INVENTION
  • The invention relates generally to β(1,4)-galactosyltransferase I mutants having altered donor and acceptor specificities, and methods of use thereof. In addition, the invention relates to methods for using the β(1,4)-galactosyltransferase I mutants to increase the immunogenicity of an antigen, such as vaccines, and for synthesizing saccharide compositions.
    • BACKGROUND OF THE INVENTION
  • Oligosaccharides are chains composed of saccharide units, which are commonly known as sugars. Of the biological polymer families, oligosaccharides are the least studied, due in part to the difficulty of sequencing and synthesizing their complex sugar chain. Currently, no generally applicable synthetic technique for synthesizing oligosaccharides is available.
  • Intensive research efforts have been devoted to carbohydrates and molecules comprising carbohydrate fragments, such as glycolipids and glycoproteins. Research interest in these moieties has been largely due to the recognition that interaction between proteins and carbohydrates are involved in a wide array of biological recognition events, including fertilization, molecular targeting, intracellular recognition, and viral, bacterial, and fungal pathogenesis. It is now widely appreciated that the oligosaccharide portions of glycoproteins and glycolipids mediate cell-cell interactions, cell-ligand interactions, cell-extracellular matrix interactions, and cell-pathogen interactions.
  • It is thought that many of these interactions can be inhibited by oligosaccharides that have the same sugar sequence and stereochemistry found on the active portion of a glycoprotein or glycolipid involved in the interactions. The oligosaccharides are believed to compete with the glycoproteins and glycolipids for binding sites on the receptor proteins. For example, the disaccharide galactosyl-β(1,4)-N-acetylglucosamine is believed to be one component of the glycoprotein which interacts with receptors in the plasma membrane of liver cells. Thus, oligosaccharides and other saccharide compositions that mimic ligands recognized and bound by cellular receptors are thought to be useful in applications that include diagnostics and therapeutics.
  • In addition to mediating numerous cellular interactions, many oligosaccharides are recognized by the immune system. For example, Anti-Gal, a naturally occurring antibody present in all humans, specifically interacts with the carbohydrate epitope Gal-α(1-3)Gal-β(1-4)GlcNAc-R (α-galactosyl epitope). This antibody does not interact with any other known carbohydrate epitope produced by mammalian cells (Galili, Springer Seminar Immunopathology, 15:153 (1993)). Anti-Gal constitutes approximately 1% of circulating IgG (Galili et al., J. Exp. Med., 160:1519 (1984)) and is also found in the form of IgA and IgM (Davine et al., Kidney Int., 31:1132 (1987); Sandrin et al., Proc. Natl. Acad. Sci., 90:11391 (1993)). It is produced by 1% of circulating B-lymphocytes (Galili et al., Blood, 82:2485 (1993)). Accordingly, the ability of carbohydrates to elicit an immune response can be utilized to increase the effectiveness of vaccines against many types of pathogens by linking such a carbohydrate to a vaccine to increase the immune response to the vaccine.
  • There has been relatively little effort to test oligosaccharides as therapeutic agents for humans or animal diseases however, as methods to synthesize oligosaccharides have been unavailable as noted above. Limited types of small oligosaccharides can be custom-synthesized by organic chemical methods, but the cost of such compounds is typically prohibitively high. In addition, it is very difficult to synthesize oligosaccharides stereospecifically and the addition of some sugars, such as sialic acid and fucose, has not been effectively accomplished because of the extreme lability of their bonds. Improved, generally applicable methods for oligosaccharide synthesis are thereby desired for the production of large amounts of widely varying oligosaccharides for therapeutic purposes. Accordingly, the present invention provides enzymes and methods that can be used to promote the chemical linkage of numerous sugars that have previously been difficult to link.
    • SUMMARY OF THE INVENTION
  • The invention provides altered β(1,4)-galactosyltransferase I catalytic domains that catalyze the formation of a glucose-β(1,4)-N-acetylglucosamine bond at a greater rate than the catalytic domain of the corresponding wild-type enzyme. The invention also provides β(1,4)-galactosyltransferase I catalytic domains that catalyze formation of N-acetylgalactosamine-β(1,4)-N-acetylglucosamine bonds; N-acetylgalactosamine-β(1,4)-glucose bonds; N-acetylglucosamine-β(1,4)-N-acetylglucosamine bonds; mannose-β(1,4)-N-acetylglucosamine bonds; and galactose-β(1,4)-N-acetylglucosamine-6-SO3 bonds. The invention also provides polypeptides that contain each of the aforementioned catalytic domains.
  • Also provided by the invention are amino acid segments that promote in vitro folding of catalytic domains of galactosyltransferases, such as β(1,4)-galactosyltransferase I, and mutants of galactosyltransferases.
  • The invention provides nucleic acid segments that encode the aforementioned β(1,4)-galactosyltransferase I catalytic domains. Expression cassettes and cells that include nucleic acid segments that encode the aforementioned β(1,4)-galactosyltransferase I catalytic domains are also provided.
  • Additionally provided are methods to synthesize a glucose-β(1,4)-N-acetylglucosamine moiety; an N-acetylgalactosamine-β(1,4)-N-acetylglucosamine moiety; an N-acetylgalactosamine-β(1,4)-glucose moiety; an N-acetylglucosamine-β(1,4)-N-acetylglucosamine moiety; a mannose-β(1,4)-N-acetylglucosamine moiety; and a galactose-β(1,4)-N-acetylglucosamine-6-SO3 moiety.
  • The invention also provides methods to increase the immunogenicity of an antigen, and methods to prepare an oligosaccharide composition, including those having a defined sequence.
  • Further provided by the invention are oligosaccharides produced through use of the catalytic domains and methods disclosed herein.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 illustrates the catalytic activity of the wt-Gal-T1 and the mutants Y289L, Y289I, and Y289N. (A) Gal-T activity of wt-Gal-T1 and of mutants at the saturating concentrations of β-benzyl-GlcNAc as the acceptor. (B) GalNAc-T activity of the wt-Gal-T1 and of mutants. The activities are measured with 50 mM β-benzyl-GlcNAc as acceptors at different concentrations of the donor. The Gal-T activity of the wt-Gal-T1 was measured with only 10 mM β-benzyl-GlcNAc because it exhibited inhibition at 50 mM concentration.
  • FIG. 2 illustrates the partial 1H NMR spectrum of the disaccharide (LacdiNAc) product from the GalNAc-T reaction with GlcNAc as the acceptor. The signal for the GalNAc anomeric proton is at δ 4.58 ppm and for the GlcNAc anomeric proton corresponding to an α and β conformer is at δ 5.2 and 4.7 ppm. The signals from the acetyl group of each sugar moiety are at δ 2.05 and 2.08 ppm.
  • FIG. 3 illustrates the cDNA sequence of the inserts and the derived protein sequences of the constructs in the pET23a vector used for studying the effect of the N-terminal stem region (SR) on the solubility and folding of the catalytic domain (CD) of β4Gal-T. (A) Sequence of bovine SRCD β4Gal-T1 having Ser 96 in the wild-type of β4Gal-T1 mutated to Ala 96, corresponding to SEQ ID NO: 9. (B) Sequence of human SRCDβ4Gal-T1, corresponding to SEQ ID NO: 6. The numbers above the amino acids correspond to the residues that delineate the stem region. An 11 amino acid extension (not shown) is located at the amino-terminal end of the protein and is coded by the pET23a vector leader sequence. The stem region sequence is shaded, followed by the catalytic domain (CD) sequence. The primers used for PCR amplification are underlined.
  • FIG. 4 shows an SDS-PAGE analysis of the recombinant CD and SRCD proteins of βb 4Gal-T produced in E. coli. Purified inclusion bodies were analyzed on 14% SDS-PAGE. Lane 1, bovine CDβ4Gal-T1; Lane 2, bovine SRCDβ4Gal-T1; Lane 3, human CDβ4Gal-T1; and Lane 4, human SRCDβ4Gal-T1.
  • FIG. 5 shows folding of inclusion bodies under different renaturation conditions: the relative activities of CDβ4Gal-T1 and SRCDβ4Gal-T1. The relative activity was calculated with respect to the folding condition I. The largest amount of folded CDβ4Gal-T1 and SRCDβ4Gal-T1 was obtained under condition VIII. The enzyme activity under condition I for CDβ4Gal-T1 was 0.052 pmol/min/ng, and for SRCDβ4Gal-T1 0.09 pmol/min/ng of N-acetyllactosamine.
  • FIG. 6 shows analysis of the soluble proteins obtained after renaturation of inclusion bodies by SDS-PAGE electrophoresis. Under native conditions (−), (without boiling and in the absence of β-ME) and under denaturing conditions (+) (samples boiled in the presence of β-ME). Lane 1: bovine CDβ4Gal-T1; Lane 2: bovine SRCDβ4Gal-T1; Lane 3: human CDβ4Gal-T1; and Lane 4: human SRCDβ4Gal-T1. Under native conditions a portion of the soluble SRCD sample representing misfolded proteins does not enter the gel (arrow 1 in lanes 2 and 4).
  • FIG. 7 illustrates binding and characterization of folded CDβ4Gal-T1 and SRCDβ4Gal-T1 on UDP-agarose columns. The purity of the proteins was judged using SDS-PAGE analysis under native conditions in the absence of #ME and without boiling the samples. The protein sample before loading on the UDP-agarose column (U) and after eluting with 25 mM EDTA and 1 M NaCl (B). Panel (A) shows the results with the human CDβ4Gal-T1 before and after passing through the UDP-agarose column, (bovine CDβ4Gal-T1 [not shown] behaves in the same way). Panel (B) shows the results with bovine SRCDβ4Gal-T1, and Panel (C) shows the results with human SRCDβ4Gal-T1. The arrows at the top of the lanes in panels B and C show the presence of soluble but misfolded proteins.
  • FIG. 8 shows the enzymatic activity of the soluble human and bovine SRCDβ4Gal-T1 proteins before and after UDP-agarose purification. The galactosyltransferase activities were measured as described herein. Specific activities of these proteins before binding ((−), black bars) and of the eluates after passing through the UDP-agarose column ((+), cross-hatched bars) are shown. (A) Buffer condition I (without PEG-4000 and L-arginine), showed more misfolded molecules in the human SRCDβ4Gal-T1 compared to bovine SRCDβ4Gal-T1. (B) Condition VIII (with PEG-4000 and L-arginine) showed more properly folded proteins in the human SRCDβ4Gal-T1 compared to bovine SRCDβ4Gal-T1 (black bars). CDβ4Gal-T1 showed difference in the amounts of folded proteins before and after binding on the UDP-agarose columns either with folding condition I or condition VIII (data not shown).
  • FIG. 9 is a schematic diagram of the in vitro folding of CD and SRCD domains of β4Gal-T1. The unfolded CD and SRCD domains during the in vitro folding step are thought to generate folding intermediates (I) and (II), respectively, which produce misfolded and properly folded molecules. The misfolded molecules of CD, (III) are mostly insoluble and precipitate out, whereas properly folded molecules (IV) are soluble, remain in solution and bind to a UDP-agarose column. SRCD misfolded (III′) and properly folded molecules (IV′) are mostly soluble. Due to the solubility effect of SR domain the proportion of the properly folded SRCD molecules increased during the folding process. The misfolded SRCD molecules, although soluble, did not significantly bind to UDP-agarose columns (III′). Properly folded SRCD molecules bind (IV′) and elute from the UDP-agarose column. The presence of PEG-4000 and L-arginine in the folding solution increased the proportion of the properly folded molecules.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • β1,4)-galactosyltransferase I catalyzes the transfer of galactose from the donor, UDP-galactose, to an acceptor, N-acetylglucosamine, to form a galactose-β(1,4)-N-acetylglucosamine bond. This reaction allows galactose to be linked to an N-acetylglucosamine that may itself be linked to a variety of other molecules. Examples of these molecules include other sugars and proteins. The reaction can be used to make many types of molecules having great biological significance. For example, galactose-β(1,4)-N-acetylglucosamine linkages are important for many recognition events that control how cells interact with each other in the body, and how cells interact with pathogens. In addition, numerous other linkages of this type are also very important for cellular recognition and binding events as well as cellular interactions with pathogens, such as viruses. Therefore, methods to synthesize these types of bonds have many applications in research and medicine to develop pharmaceutical agents and improved vaccines that can be used to treat disease.
  • The present invention is based on the surprising discovery that the enzymatic activity of β(1,4)-galactosyltransferase can be altered such that the enzyme can make chemical bonds that are very difficult to make by other methods. These alterations involve mutating the enzyme such that the mutated enzyme can transfer many different types of donors, sugars for example, to many different types of acceptors. Therefore, the mutated β(1,4)-galactosyltransferases of the invention can be used to synthesize a variety of products that, until now, have been very difficult and expensive to produce.
  • The invention also provides amino acid segments that promote the proper folding of a galactosyltransferase catalytic domain. The amino acid segments may be used to properly fold the galactosyltransferase catalytic domains of the invention and thereby increase their activity. The amino acid segments may also be used to increase the activity of galactosyltransferases that are produced recombinantly. Accordingly, use of the amino acid segments according to the invention allows for production of β(1,4)-galactosyltransferases having increased enzymatic activity relative to β(1,4)-galactosyltransferases produced in the absence of the amino acid segments.
    • DEFINITIONS
  • Abbreviations: stem region/catalytic domain β(1,4)-Galactosyltransferase I (SRCDβ4Gal-T1); catalytic domain of β(1,4)-Galactosyltransferase I (CDβ4Gal-T1); β(1,4)-Galactosyltransferase I (β4Gal-T1); catalytic domain (CD); stem region (SR); wild-type (wt); galactosyltransferase activity (Gal-T); beta-mercaptoethanol (β-ME); N-acetylgalactosamine transferase activity (GalNAc-T); α-Lactalbumin (LA).
  • The term “acceptor” refers to a molecule or structure onto which a donor is actively linked through action of a catalytic domain of a galactosyltransferase, or mutant thereof. Examples of acceptors include, but are not limited to, carbohydrates, glycoproteins, and glycolipids.
  • The term “catalytic domain” refers to an amino acid segment which folds into a domain that is able to catalyze the linkage of a donor to an acceptor. For example, a catalytic domain may be from, but is not limited to, bovine β(1,4)-Galactosyltransferase I (Seq ID NO: 5), the catalytic domain from human β(1,4)-Galactosyltransferase I (Seq ID NO: 3), or the catalytic domain from mouse β(1,4)-Galactosyltransferase I (Seq ID NO: 4). A catalytic domain may have an amino acid sequence found in a wild-type enzyme, or may have an amino acid sequence that is different from a wild-type sequence. For example, a catalytic domain may have an amino acid sequence that corresponds to amino acid residues 130402 of SEQ ID NO: 5, expect that the lysine is exchanged with arginine at amino acid position 228.
  • The term “donor” refers to a molecule that is actively linked to an acceptor molecule through the action of a catalytic domain of a galactosyltransferase, or mutant thereof. A donor molecule can include a sugar, or a sugar derivative. Examples of donors include, but are not limited to, UDP-galactose, UDP-mannose, UDP-N-acetylglucosamine, UDP-glucose, GDP-mannose, UDP-N-acetylgalactosamine, UDP-glucuronic acid, GDP-Fucose, and CMP-N-acetylneuraminic acid. Donors include sugar derivatives that include active groups, such as cross-linking agents or labeling agents. Accordingly, oligosaccharides may be prepared according to the methods of the invention that include a sugar derivative having a desired characteristic.
  • “Expression cassette” as used herein means a DNA sequence capable of directing expression of a particular nucleotide sequence in an appropriate host cell, comprising a promoter operably linked to the nucleotide sequence of interest that is operably linked to termination signals. It also typically comprises sequences required for proper translation of the nucleotide sequence. The expression cassette may be one that is naturally occurring but has been obtained in a recombinant form useful for heterologous expression. The expression of the nucleotide sequence in the expression cassette may be under the control of a constitutive promoter or of an inducible promoter that initiates transcription only when the host cell is exposed to some particular external stimulus. In the case of a multicellular organism, the promoter can also be specific to a particular tissue or organ or stage of development.
  • The terms oligosaccharide and polysaccharide are used interchangeably herein. These terms refer to saccharide chains having two or more linked sugars. Oligosaccharides and polysaccharides may be homopolymers and heteropolymers having a random sugar sequence or a preselected sugar sequence. Additionally, oligosaccharides and polysaccharides may contain sugars that are normally found in nature, derivatives of sugars, and mixed polymers thereof.
  • “Polypeptides” and “Proteins” are used interchangeably herein. Polypeptides and proteins can be expressed in vivo through use of prokaryotic or eukaryotic expression systems. Many such expressions systems are known in the art and are commercially available. (Clontech, Palo Alto, Calif.; Stratagene, La Jolla, Calif.). Examples of such systems include, but are not limited to, the T7-expression system in prokaryotes and the bacculovirus expression system in eukaryotes. Polypeptides can also be synthesized in vitro, e.g., by the solid phase peptide synthetic method or by in vitro transcription/translation systems. Such methods are described, for example, in U.S. Pat. Nos. 5,595,887; 5,116,750; 5,168,049 and 5,053,133; Olson et al., Peptides, a 301, 307 (1988). The solid phase peptide synthetic method is an established and widely used method, which is described in the following references: Stewart et al., Solid Phase Peptide Synthesis, W. H. Freeman Co., San Francisco (1969); Merrifield, J. Am. Chem. Soc., 85 2149 (1963); Meienhofer in “Hormonal Proteins and Peptides,” ed.; C. H. Li, Vol. 2 (Academic Press, 1973), pp. 48-267; Bavaay and Merrifield, “The Peptides,” eds. E. Gross and F. Meienhofer, Vol. 2 (Academic Press, 1980) pp. 3-285; and Clark-Lewis et al., Meth. Enzymol., 287, 233 (1997). These polypeptides can be further purified by fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on an anion-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; or ligand affinity chromatography.
  • The polypeptides of the invention include polypeptides having amino acid exchanges, i.e., variant polypeptides, so long as the polypeptide variant is biologically active. The variant polypeptides include the exchange of at least one amino acid residue in the polypeptide for another amino acid residue, including exchanges that utilize the D rather than L form, as well as other well known amino acid analogs, e.g., N-alkyl amino acids, lactic acid, and the like. These analogs include phosphoserine, phosphothreonine, phosphotyrosine, hydroxyproline, gamma-carboxyglutamate; hippuric acid, octahydroindole-2-carboxylic acid, statine, 1,2,3,4,-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, citruline, N-methyl-alanine, para-benzoyl-phenylalanine, phenylglycine, propargylglycine, sarcosine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, and other similar amino acids and imino acids and tert-butylglycine.
  • Conservative amino acid exchanges are preferred and include, for example; aspartic-glutamic as acidic amino acids; lysine/arginine/histidine as basic amino acids; leucine/isoleucine, methionine/valine, alanine/valine as hydrophobic amino acids; serine/glycine/alanine/threonine as hydrophilic amino acids. Conservative amino acid exchange also includes groupings based on side chains. Members in each group can be exchanged with another. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine. These may be exchanged with one another. A group of amino acids having aliphatic-hydroxyl side chains is serine and threonine. A group of amino acids having amide-containing side chains is asparagine and glutamine. A group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan. A group of amino acids having basic side chains is lysine, arginine, and histidine. A group of amino acids having sulfur-containing side chains is cysteine and methionine. For example, replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid may be accomplished to produce a variant polypeptide of the invention.
    • I. β(1.4)-Galactosyltransferase I Catalytic Domains of the Invention.
  • A. Catalytic Domains that Catalyze the Formation of a Bond Between a Donor and an Acceptor to Form Glucose-β(1.4)-N-acetylglucosamine Bonds.
  • It has been discovered that mutation of the donor binding site of β(1,4)-galactosyltransferase I can broaden the donor specificity of the enzyme. More specifically, it has been determined that substitution of amino acid residues located in the donor binding site of β(1,4)-galactosyltransferase I to provide greater flexibility and decreased steric hindrance allow glucose to be bound and chemically bonded to N-acetylglucosamine. Such mutations provide for broadened donor binding, such as binding of glucose, while still preserving interaction with amino acid residues active during catalytic bond formation between the donor and the acceptor. Without being bound by any theory, an example of a catalytic residue thought to be important for catalysis is a glutamic acid positioned at amino acid position 317 (E317) in the bovine β(1,4)-galactosyltransferase I. This glutamic acid in bovine β(1,4)-galactosyltransferase I corresponds to a glutamic acid residue at amino acid position 313 and at amino acid position 314 in the human and mouse β(1,4)-galactosyltransferase I respectively. Accordingly, the invention provides β(1,4)-galactosyltransferase I mutants having amino acid substitutions, insertions, and deletions that provide greater flexibility and decreased steric hindrance in the donor binding site to allow the mutated β(1,4)-galactosyltransferase I to catalyze chemical bonding of the donor to an acceptor, such as N-acetylglucosamine or glucose.
  • In some embodiments, the catalytic domains of the invention have an arginine exchanged with another amino acid at an amino acid position corresponding to 228 in the bovine β(1,4)-galactosyltransferase I (SEQ ID NO: 5). An example of a specific exchange is R228K. The corresponding arginine in the human and mouse β(1,4)-galactosyltransferase I is located at amino acid position 224 and 225 (SEQ ID Nos: 3 and 4 respectively). In mouse, human, and bovine β(1,4)-galactosyltransferase I, the arginine is located within the amino acid sequence FNRAKLL (SEQ ID NO: 1). Accordingly, those of skill in the art can readily determine an equivalent amino acid in other β(1,4)-galactosyltransferase I catalytic domains.
  • In other embodiments, the catalytic domains of the invention have an arginine exchanged with another amino acid at an amino acid position corresponding to 228, and an alanine exchanged with another amino acid at an amino acid position corresponding to 229 in the bovine β(1,4)-galactosyltransferase I.
  • Such catalytic domains are exemplified by a catalytic domain of bovine β(1,4)-galactosyltransferase I having the arginine at amino acid position 228 exchanged with lysine (R228K), and the alanine at amino acid position 229 exchanged with glycine (A229G). The corresponding alanine in the human and mouse β(1,4)-galactosyltransferase I is located at amino acid position 225 and 226 (SEQ ID Nos: 3 and 4 respectively). In mouse, human, and bovine β(1,4)-galactosyltransferase I, the arginine is located within the amino acid sequence FNRAKLL (SEQ ID NO: 1). Accordingly, those of skill in the art can readily determine an equivalent amino acid in other β(1,4)-galactosyltransferase I catalytic domains.
  • B. Catalytic Domains that Catalyze the Formation of a Bond Between a Donor and an Acceptor to Form N-acetylgalactosamine-β(1.4)-N-acetylglucosamine Bonds.
  • It was postulated that formation of a hydrogen bond between N-acetylgalactosamine and an amino acid residue adjoining the donor binding site in β(1,4)-galactosyltransferase I is responsible for poor transfer of N-acetylgalactosamine to an acceptor. It was also postulated that mutation of one or more amino acid residues in the donor binding site in β(1,4)-galactosyltransferase I to eliminate hydrogen bond formation with N-acetylgalactosamine allows the mutated β(1,4)-galactosyltransferase I to transfer N-acetylgalactosamine from a donor to an acceptor more efficiently. Therefore, the invention includes mutants of β(1,4)-galactosyltransferase I in which hydrogen bonds that reduce transfer of N-acetylgalactosamine to an acceptor, such as N-acetylglucosamine or glucose, are reduced or absent.
  • In some embodiments, the catalytic domains of the invention have a tyrosine exchanged with another amino acid at an amino acid position corresponding to 289 in the bovine β(1,4)-galactosyltransferase I (SEQ ID NO: 5). Examples of specific exchanges are Y289L, Y289I, and Y289N. The corresponding tyrosine in the human and mouse β(1,4)-galactosyltransferase I is located at amino acid position 285 and 286 (SEQ ID Nos: 3 and 4 respectively). In mouse, human, and bovine β(1,4)-galactosyltransferase I, the tyrosine is located within the amino acid sequence YVQYFGG (SEQ ID NO: 2). Accordingly, those of skill in the art can readily determine equivalent amino acids in other β(1,4)-galactosyltransferase I catalytic domains.
  • Mutants in which the tyrosine corresponding to that located at amino acid position 289 in the bovine β(1,4)-galactosyltransferase I has been exchanged by another amino acid may optionally include a second mutation corresponding to amino acid position 342. Such a mutation may include exchange of cysteine at amino acid position 342 with threonine (C342T). However, other amino acids may be exchanged for cysteine that provide and active catalytic domain.
  • C. Catalytic Domains that Catalyze the Formation of a Bond Between a Donor and an Acceptor to Form N-acetylgalactosamine-β(1.4)-glucose Bonds.
  • β(1,4)-galactosyltransferase I mutants, as described herein, that are able to catalyze chemical bond formation of N-acetylgalactosamine to an acceptor may be used in conjunction with α-lactalbumin to catalyze the formation of N-acetylgalactosamine-β(1,4)-glucose bonds.
  • α-Lactalbumin is a mammary gland-specific calcium-binding protein that alters the sugar acceptor specificity of β(1,4)-galactosyltransferase I toward glucose. Consequently, α-lactalbumin may be used to alter the acceptor specificity β(1,4)-galactosyltransferase I, and mutants thereof that are described herein, to efficiently catalyze N-acetylgalactosamine-β(1,4)-glucose bond formation. Conditions for use of α-lactalbumin in conjunction with a galactosyltransferase, or active domain thereof, have been described (Ramakrishnan et al., J. Biol. Chem., 276:37665 (2001)).
  • D. Catalytic Domains that Catalyze the Formation of a Bond Between a Donor and an Acceptor to form N-acetylglucosamine-β(1.4)-N-acetylglucosamine Bonds, Oligo N-acetylgalactosamine-β(1,4)-N-acetylglucosamine, and mannose-β(1,4) -N-acetylglucosamine.
  • The mutations described herein may be combined to create catalytic domains having selectively altered donor specificities. For example, a catalytic domain obtained from bovine β(1,4)-galactosyltransferase I having exchanges at amino acid positions 228 (R228K) and 289 (Y289L) was able to catalyze the linkage of N-acetylglucosamine to N-acetylglucosamine to form a N-acetylglucosamine-β(1,4)-N-acetylglucosamine bond. The same mutant catalytic domain was able to catalyze the linkage of N-acetylgalactosamine to N-acetylglucosamine to form oligo N-acetylgalactosamine-β(1,4)-N-acetylglucosamine. The broadened donor specificity was further demonstrated by the ability of the mutant catalytic domain to catalyze the linkage of mannose to N-acetylglucosamine to form mannose-β(1,4)-N-acetylglucosamine. Accordingly, numerous mutant catalytic domains having altered donor specificity may be created by mutating amino acids corresponding to those at positions corresponding to 228 and 289 of the bovine β(1,4)-galactosyltransferase I. As described above, these amino acid positions may be readily determined in galactosyltransferase enzymes obtained from other organisms, such as humans, and mutated in produce additional catalytic domains having altered donor specificity.
  • E. Catalytic Domains that Catalyze the Formation of a Bond Between a Donor and an Acceptor Having a Bulky Side-Group to Form for Example, Galactose-β(1.4)-N-acetylglucosamine-6-SO3 Bonds.
  • The acceptor specificity of a catalytic domain obtained from a galactosyltransferase may be altered to create catalytic domains capable of transferring a donor onto an acceptor having a bulky and/or charged side-group.
  • An example of such an altered catalytic domain obtained from bovine β(1,4)-galactosyltransferase I has substitutions at amino acid positions 279 (K279S) and 280 (F280T). This altered catalytic domain is able to catalyze the transfer of galactose to N-acetylglucosamine-6-SO3 to form galactose-β(1,4)-N-acetylglucosamine-6-SO3. Additional catalytic domains may be created by altering one or more amino acid residues at positions corresponding to 279 and 280 of the bovine β(1,4)-galactosyltransferase I. As described above, these amino acid positions may be readily determined in galactosyltransferase enzymes obtained from other organisms, such as humans, and mutated in produce additional catalytic domains having altered acceptor specificity.
  • The amino acids at positions corresponding to 279 and 280 in the bovine β(1,4)-galactosyltransferase I may be exchanged individually or together to create many different catalytic domains having altered acceptor sites able to accept numerous acceptors having bulky (sterically large) or charged side-groups. Such altered catalytic domains may be used to catalyze linkage of sugars from a donor to an acceptor having a desired side-chain.
  • II. Catalytic Domains of the Invention May be Included within Full-Length β(1.4)-galactosyltransferase I Enzymes, or in Recombinant Molecules Containing the Catalytic Domains.
  • Peptides of the invention include isolated catalytic domains, full-length β(1,4)-galactosyltransferase I enzymes containing a catalytic domain of the invention, as well as recombinant polypeptides comprising a catalytic domain of the invention that are linked to additional amino acids. Such polypeptides may be expressed from DNA constructs and expression cassettes that are produced through use of recombinant methods. Such methods have been described. Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (2001).
  • Galactosyltransferase enzymes containing a catalytic domain of the invention may be produced in soluble form. Methods that may be used to produce such soluble enzymes have been described (U.S. Pat. No. 5,032,519). Briefly, a hydrophobic transmembrane anchor region of a galactosyltransferase is removed to produce an enzyme that is in soluble form.
  • Alternatively, β(1,4)-galactosyltransferase enzymes containing a catalytic domain of the invention may be produced such that they are anchored in the membrane of a cell that expresses the galactosyltransferase. Such enzymes may be produced that are anchored in the membranes of prokaryotic and eukaryotic cells. Methods to produce such enzymes have been described (U.S. Pat. No. 6,284,493).
  • Briefly, in the case of procaryotes, the signal and transmembrane sequences of the galactosyltransferase are replaced by a bacterial signal sequence, capable of effecting localization of the fusion protein to the outer membrane. Suitable signal sequences include, but are not limited to those from the major E. coli lipoprotein Lpp and lam B. In addition, membrane spanning regions from Omp A, Omp C, Omp F or Pho E can be used in a tripartite fusion protein to direct proper insertion of the fusion protein into the outer membrane. Any procaryotic cells can be used in accordance with the present invention including but not limited to E. coli, Bacillus sp., and Pseudomonas sp. as representative examples.
  • In another embodiment, the native transmembrane domain of the galactosyltransferase is replaced by the transmembrane domain of a bacterial outer membrane protein. In this embodiment, the galactosyltransferase signal sequence and the bacterial transmembrane region act in concert to anchor the galactosyltransferase to the bacterial outer cell membrane. Nearly any outer membrane bound protein is suitable for this use including but not limited to Omp A, Omp C, and Omp F, Lpp, and Lam B. The catalytic portion of the galactosyltransferase should be fused to an extracellular loop in the bacterial transmembrane region in order to insure proper orientation of the fusion protein on the outer membrane surface and not in the cytoplasm or periplasm of the cell. Insertion of a protein into such a loop region has been previously reported (Charbit et al., J. Bacteriology, 173:262 (1991); Francisco et al., Proc. Natl. Acad. Sci., 89:2713 (1992)).
  • The present invention is also applicable for use with eukaryotic cells resulting in cell surface expression of galactosyltransferases in known culturable eucaryotic cells including but not limited to yeast cells, insect cells, chinese hamster ovary cells (CHO cells), mouse L cells, mouse A9 cells, baby hamster kidney cells, C127 cells, COS cells, Sf9 cells, and PC8 cells.
  • In another embodiment of the present invention, the transmembrane domain of the galactosyltransferase is replaced by the transmembrane domain of a plasma membrane protein. The transmembrane domain of any resident plasma membrane protein will be appropriate for this purpose. The transmembrane portions of the M6 P/IGF-II receptor, LDL receptor or the transferrin receptor are representative examples.
  • In another embodiment the Golgi retention signal of the galactosyltransferase is disrupted by site-directed mutagenesis. This approach mutates the amino acids responsible for localizing the galactosyltransferase to the Golgi compartment. The resultant galactosyltransferase is transported to the plasma membrane where it becomes anchored via its modified transmembrane sequences. Substitution of isoleucine residues for the native amino acids in the transmembrane region of the β(1,4)galactosyltransferase has been shown to preferentially localize the enzyme to the plasma membrane instead of the Golgi apparatus (Masibay et al., J. Biol. Chem., 268:9908 (1993)).
  • III. A Stem Region that Promotes the In Vitro Folding of a Catalytic Domain of a Galactosyltransferase.
  • β(1,4)-galactosyltransferase I is a type II Golgi resident protein with a short cytoplasmic tail, a transmembrane domain followed by a stem region and has a globular catalytic domain that faces the Golgi lumen. When the catalytic domain of β(1,4)-galactosyltransferase I is expressed in E. coli, it forms insoluble inclusion bodies. These inclusion bodies can be collected and then solubilized and folded in vitro to produce catalytically active domains. Thus, the in vitro folding efficiency is directly related to the quantity of active enzyme that is produced from the isolated inclusion bodies. Accordingly, methods to increase the in vitro folding efficiency would provide increased production of catalytic domains that can be used to create useful products.
  • The invention provides materials and methods that improve in vitro folding of catalytic domains from galactosyltransferases that are related to the use of a stem region (for example, SEQ ID NOs: 6 and 7) of β(1,4)-galactosyltransferase I. It has been determined that fusion of a stem region from a β(1,4)-galactosyltransferase I to the amino-terminus of the catalytic domain of a β(1,4)-galactosyltransferase I produces increased in vitro folding efficiency of the catalytic domain. This increase in folding is thought to be universal among β(1,4)-galactosyltransferase I enzymes and was demonstrated with both the bovine and human enzymes.
  • It has been further discovered that inclusion of PEG-4000 and L-Arg in the folding reaction results in a four-fold to seven-fold increase in catalytic domains that are natively folded when compared to refolding of the catalytic domain alone in the absence of PEG-4000 and L-Arg. PEG-4000 and L-arginine are thought to beneficially affect the solubility of folding intermediates of both catalytic domain-proteins (CD-proteins) and stem region/catalytic domain proteins (SRCD-proteins) during in vitro folding or protein obtained from inclusion bodies. The presence of PEG-4000 and L-arginine during in vitro folding enhanced the formation of both native and misfolded molecules. The processes involved are schematically shown in FIG. 9. In the case of CD-proteins, the majority of misfolded proteins are insoluble in the absence of PEG-4000 and L-arginine and thus, they precipitate out during dialysis. This process left behind the properly folded molecules in solution that bound to UDP-agarose and were enzymatically active. (FIG. 8) (Table IX). It is thought that the SR-domain, like PEG-4000 and L-arginine, helped to solubilize the folding intermediates, and hence enhanced the formation of both native and misfolded-SRCD molecules. The presence of PEG-4000 and L-arginine enhanced the solubilization of the folding intermediates of SRCD-molecules even further. The misfolded SRCD proteins, in contrast to the majority of CD-proteins, remained soluble even in the absence of PEG-4000 and L-arginine. Therefore, the misfolded SRCD-proteins were not removed as precipitates during dialysis. Misfolded SRCD-proteins can be separated from properly folded proteins through binding on UDP-agarose columns (Table IX). Thus the SR-domain is thought to act as a solubilizing agent both for the misfolded and folded catalytic domain. It is thought that the increased solubility of SRCD-proteins is produced by preventing aggregation of misfolded proteins. In this respect its mode of action is thought to resemble the action of chaperone proteins. The positive effect of the N-terminal stem region in the folding and stability of the native protein is very useful for producing large quantities of other galactosyltransferase family members.
  • The in vitro folding efficiency of bovine β(1,4)-galactosyltransferase I was further increased by substituting the cysteine at amino acid position 342 with a threonine (C342T). Analogous mutations can be made in β(1,4)-galactosyltransferase I enzymes from other organisms.
  • It was determined that the wild-type bovine SRCDβ4Gal-T1, folded and purified from inclusion bodies, was cleaved at Ser96 within the stem region over a short period of time. Therefore, to decrease degradation of bovine SRCDβ4Gal-T1, the serine at amino acid position 96 was exchanged with an Ala to produce S96A-SRCDβ4Gal-T1. After folding and purification from bacterial inclusion bodies, S96A-SRCDβ4Gal-T1 was found to be more stable over a long period of time when compared to SRCDβ4Gal-T1, which did not include the S96A mutation. S96A-SRCDβ4Gal-T1 was used within some of the in vitro folding studies disclosed herein.
  • The in vitro folding efficiency of catalytic domains that include a stem region in the presence of PEG-4000 and L-Arg was about 50 percent and the solubility of the refolded product was about 90 percent.
  • Accordingly, the invention includes stem regions from members of the galactosyltransferase family that can be fused to a catalytic domain of a galactosyltransferase to provide increased in vitro folding of the catalytic domain. Such stem regions can be readily determined based on amino acid sequence homology to the bovine stem region and tested for the ability to promote folding of a galactosyltransferase catalytic domain. The invention also includes the mutants disclosed herein and their corresponding analogs in other species.
  • General methods for isolating and folding inclusion bodies containing galactosyltransferase catalytic domains have been previously described (Ramakrishnan et al., J. Biol. Chem. 276:37665 (2001)). These methods may be used in conjunction with the stem region of the invention, PEG4000, and L-Arg to increase the folding efficiency of a galactosyltransferase catalytic domain. These methods are described in the examples section herein.
  • IV. Nucleic Acid Segments Encoding Catalytic Domains of β(1.4)-galactosyltransferase I, Expression Cassettes that Include the Nucleic Acid Segments, and Cells that Include the Nucleic Acid Segments and Expression Cassettes.
  • The present invention provides isolated nucleic acid segments that encode catalytic domains of β(1,4)-galactosyltransferase I having altered donor or acceptor specificity. The present invention also provides nucleic acid segments that encode amino acid segments that promote proper folding of catalytic domains from galactosyltransferases, such as β(1,4)-galactosyltransferase I.
  • Nucleic acid sequences encoding human β(1,4)-galactosyltransferase I (SEQ ID NO: 8), as well as other β(1,4)-galactosyltransferases I from other organisms are available. These nucleic acid sequences can be modified to encode the catalytic domains and amino acid segments of the invention through use of well-known techniques (Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (2001)). For example, a portion of the nucleic acid sequence encoding human β(1,4)-galactosyltransferase I (SEQ ID NO: 8) can be inserted into an expression vector such that an amino acid segment corresponding to the catalytic domain of human β(1,4)-galactosyltransferase I (SEQ ID NO: 6) is expressed upon transformation of a cell with the expression vector. In another example, bovine β(1,4)-galactosyltransferase I can be altered to replace the tyrosine at amino acid position 289 with leucine, isoleucine, or asparagine through use of site-directed mutagenesis (Ramakrishnan et al., J. Biol. Chem., 277:20833 (2002)). Similar methods may be used to produce nucleic acid segments encoding additional mutants and catalytic domains described herein.
  • The nucleic acid segments of the invention may be optimized for expression in select cells. Codon optimization tables are available. Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1988.
  • The nucleic acid segments can be inserted into numerous types of vectors. A vector may include, but is not limited to, any plasmid, phagemid, F-factor, virus, cosmid, or phage in double or single stranded linear or circular form which may or may not be self transmissible or mobilizable. The vector can also transform a prokaryotic or eukaryotic host either by integration into the cellular genome or exist extrachromosomally (e.g. autonomous replicating plasmid with an origin of replication).
  • Preferably the nucleic acid segment in the vector is under the control of, and operably linked to, an appropriate promoter or other regulatory elements for transcription in vitro or in a host cell such as a eukaryotic cell or microbe, e.g. bacteria. The vector may be a bi-functional expression vector which functions in multiple hosts. In the case of genomic DNA, this may contain its own promoter or other regulatory elements and in the case of cDNA this may be under the control of a promoter or other regulatory sequences for expression in a host cell.
  • Specifically included are shuttle vectors by which is meant a DNA vehicle capable, naturally or by design, of replication in two different host organisms, which may be selected from bacteria and eukaryotic cells (e.g. mammalian, yeast or fungal).
  • The vector may also be a cloning vector which typically contains one or a small number of restriction endonuclease recognition sites at which nucleic acid segments can be inserted in a determinable fashion. Such insertion can occur without loss of essential biological function of the cloning vector. A cloning vector may also contain a marker gene that is suitable for use in the identification and selection of cells transformed with the cloning vector. Examples of marker genes are tetracycline resistance, hygromycin resistance or ampicillin resistance. Many cloning vectors are commercially available (Stratagene, New England Biolabs, Clonetech).
  • The nucleic acid segments of the invention may also be inserted into an expression vector. Typically an expression vector contains (1) prokaryotic DNA elements coding for a bacterial replication origin and an antibiotic resistance gene to provide for the amplification and selection of the expression vector in a bacterial host; (2) regulatory elements that control initiation of transcription such as a promoter; and (3) DNA elements that control the processing of transcripts such as introns, transcription termination/polyadenylation sequence.
  • Methods to introduce a nucleic acid segment into a vector are well known in the art (Sambrook et al., 1989). Briefly, a vector into which the nucleic acid segment is to be inserted is treated with one or more restriction enzymes (restriction endonuclease) to produce a linearized vector having a blunt end, a “sticky” end with a 5′ or a 3′ overhang, or any combination of the above. The vector may also be treated with a restriction enzyme and subsequently treated with another modifying enzyme, such as a polymerase, an exonuclease, a phosphatase or a kinase, to create a linearized vector that has characteristics useful for ligation of a nucleic acid segment into the vector. The nucleic acid segment that is to be inserted into the vector is treated with one or more restriction enzymes to create a linearized segment having a blunt end, a “sticky” end with a 5′ or a 3′ overhang, or any combination of the above. The nucleic acid segment may also be treated with a restriction enzyme and subsequently treated with another DNA modifying enzyme. Such DNA modifying enzymes include, but are not limited to, polymerase, exonuclease, phosphatase or a kinase, to create a polynucleic acid segment that has characteristics useful for ligation of a nucleic acid segment into the vector.
  • The treated vector and nucleic acid segment are then ligated together to form a construct containing a nucleic acid segment according to methods known in the art (Sambrook, 2002). Briefly, the treated nucleic acid fragment and the treated vector are combined in the presence of a suitable buffer and ligase. The mixture is then incubated under appropriate conditions to allow the ligase to ligate the nucleic acid fragment into the vector. It is preferred that the nucleic acid fragment and the vector each have complimentary “sticky” ends to increase ligation efficiency, as opposed to blunt-end ligation. It is more preferred that the vector and nucleic acid fragment are each treated with two different restriction enzymes to produce two different complimentary “sticky” ends. This allows for directional ligation of the nucleic acid fragment into the vector, increases ligation efficiency and avoids ligation of the ends of the vector to reform the vector without the inserted nucleic acid fragment.
  • Suitable procaryotic vectors include but are not limited to pBR322, pMB9, pUC, lambda bacteriophage, m13 bacteriophage, and Bluescript®. Suitable eukaryotic vectors include but are not limited to PMSG, pAV009/A+, PMTO10/A+, pMAM neo-5, bacculovirus, pDSVE, YIP5, YRP17, YEP. It will be clear to one of ordinary skill in the art which vector or promoter system should be used depending on which cell type is used for a host cell.
  • The invention also provides expression cassettes which contain a control sequence capable of directing expression of a particular nucleic acid segment of the invention either in vitro or in a host cell. The expression cassette is an isolatable unit such that the expression cassette may be in linear form and functional in in vitro transcription and translation assays. The materials and procedures to conduct these assays are commercially available from Promega Corp. (Madison, Wis.). For example, an in vitro transcript may be produced by placing a nucleic acid segment under the control of a T7 promoter and then using T7 RNA polymerase to produce an in vitro transcript. This transcript may then be translated in vitro through use of a rabbit reticulocyte lysate. Alternatively, the expression cassette can be incorporated into a vector allowing for replication and amplification of the expression cassette within a host cell or also in vitro transcription and translation of a nucleic acid segment.
  • Such an expression cassette may contain one or a plurality of restriction sites allowing for placement of the nucleic acid segment under the regulation of a regulatory sequence. The expression cassette can also contain a termination signal operably linked to the nucleic acid segment as well as regulatory sequences required for proper translation of the nucleic acid segment. Expression of the nucleic acid segment in the expression cassette may be under the control of a constitutive promoter or an inducible promoter which initiates transcription only when the host cell is exposed to some particular external stimulus.
  • The expression cassette may include in the 5′-3′ direction of transcription, a transcriptional and translational initiation region, a nucleic acid segment and a transcriptional and translational termination region functional in vivo and/or in vitro. The termination region may be native with the transcriptional initiation region, may be native with the nucleic acid segment, or may be derived from another source. Numerous termination regions are known in the art. Guerineau et al., Mol. Gen. Genet., 262:141 (1991); Proudfoot, Cell, 64:671 (1991); Sanfacon et al., Genes Dev., 5:141 (1991); Munroe et al., Gene, 91:151 (1990); Ballas et al., Nucleic Acids Res., 17:7891 (1989); Joshi et al., Nucleic Acid Res., 15:9627 (1987).
  • The regulatory sequence can be a nucleic acid sequence located upstream (5′ non-coding sequences), within, or downstream (3′ non-coding sequences) of a coding sequence, and which influences the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences can include, but are not limited to, enhancers, promoters, repressor binding sites, translation leader sequences, introns, and polyadenylation signal sequences. They may include natural and synthetic sequences as well as sequences which may be a combination of synthetic and natural sequences. While regulatory sequences are not limited to promoters, some useful regulatory sequences include constitutive promoters, inducible promoters, regulated promoters, tissue-specific promoters, viral promoters and synthetic promoters.
  • A promoter is a nucleotide sequence that controls expression of the coding sequence by providing the recognition for RNA polymerase and other factors required for proper transcription. A promoter includes a minimal promoter, consisting only of all basal elements needed for transcription initiation, such as a TATA-box and/or initiator that is a short DNA sequence comprised of a TATA-box and other sequences that serve to specify the site of transcription initiation, to which regulatory elements are added for control of expression. A promoter may be inducible. Several inducible promoters have been reported (Current Opinion in Biotechnology, 7:168 (1996)). Examples include the tetracycline repressor system, Lac repressor system, copper-inducible systems, salicylate-inducible systems (such as the PR1a system). Also included are the benzene sulphonamide- (U.S. Pat. No. 5,364,780) and alcohol- (WO 97/06269 and WO 97/06268) inducible systems and glutathione S-transferase promoters. In the case of a multicellular organism, the promoter can also be specific to a particular tissue or organ or stage of development.
  • An enhancer is a DNA sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue specificity of a promoter. It is capable of operating in both orientations (normal or flipped), and is capable of functioning even when moved either upstream or downstream from the promoter. Both enhancers and other upstream promoter elements bind sequence-specific DNA-binding proteins that mediate their effects.
  • The expression cassette can contain a 5′ non-coding sequence which is a nucleotide sequence located 5′ (upstream) to the coding sequence. It is present in the fully processed mRNA upstream of the initiation codon and may affect processing of the primary transcript to mRNA, stability of the mRNA, or translation efficiency (Turner et al., Molecular Biotechnology, 3:225 (1995)).
  • The expression cassette may also contain a 3′ non-coding sequence which is a nucleotide sequence located 3′ (downstream) to a coding sequence and includes polyadenylation signal sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3′ end of the mRNA precursor.
  • The invention also provides a construct containing a vector and an expression cassette. The vector may be selected from, but not limited to, any vector previously described. Into this vector may be inserted an expression cassette through methods known in the art and previously described (Sambrook et al., 1989). In one embodiment, the regulatory sequences of the expression cassette may be derived from a source other than the vector into which the expression cassette is inserted. In another embodiment, a construct containing a vector and an expression cassette is formed upon insertion of a nucleic acid segment of the invention into a vector that itself contains regulatory sequences. Thus, an expression cassette is formed upon insertion of the nucleic acid segment into the vector. Vectors containing regulatory sequences are available commercially and methods for their use are known in the art (Clonetech, Promega, Stratagene).
  • The expression cassette, or a vector construct containing the expression cassette may be inserted into a cell. The expression cassette or vector construct may be carried episomally or integrated into the genome of the cell.
  • A variety of techniques are available and known to those skilled in the art for introduction of constructs into a cellular host. Transformation of bacteria and many eukaryotic cells may be accomplished through use of polyethylene glycol, calcium chloride, viral infection, phage infection, electroporation and other methods known in the art. Other transformation methods are available to those skilled in the art, such as direct uptake of foreign DNA constructs (see EP 295959), techniques of electroporation (Fromm et al. Nature (London), 319:791 (1986) or high velocity ballistic bombardment with metal particles coated with the nucleic acid constructs (Kline et al. Nature (London) 327:70 (1987), and U.S. Pat. No. 4,945,050).
  • The selection of an appropriate expression vector will depend upon the method of introducing the expression vector into host cells. Typically an expression vector contains (1) prokaryotic DNA elements coding for a bacterial origin of replication and an antibiotic resistance gene to provide for the amplification and selection of the expression vector in a bacterial host; (2) DNA elements that control initiation of transcription, such as a promoter; (3) DNA elements that control the processing of transcripts, such as introns, transcription termination/polyadenylation sequence; and (4) a reporter gene that is operatively linked to the DNA elements to control transcription initiation. Useful reporter genes include β-galactosidase, chloramphenicol acetyl transferase, luciferase, green fluorescent protein (GFP) and the like.
  • V. Methods to Synthesize glucose-β(1.4)-N-acetylglucosamine Moieties, N-acetylgalactosamine-β(1,4)-N-acetyl Glucosamine Moieties: N-acetylgalactosamine-β(1,4)-glucose moieties: N-acetylglucosamine-β(1.4)-N-acetylglucosamine Moieties: mannose-β(1,4)-N-acetylglucosamine Moieties; and galactose-β(1,4)-N-acetylglucosamine-6-SO3 Moieties.
  • Catalytic domains of the invention having altered donor and acceptor specificity can be used to catalyze the linkage of numerous sugars from a donor to numerous acceptor sugars. Linkage of sugar derivatives can also achieved through use of the altered catalytic domains of the invention due to their expanded donor and acceptor specificity.
  • For example, the catalytic domains of section IA can be used to catalyze the linkage of glucose and N-acetylglucosamine; the catalytic domains of section IB can be used to catalyze the linkage of N-acetylgalactosamine and N-acetylglucosamine; many of the catalytic domains described herein can be used in association with α-lactalbumin to catalyze linkage of a sugar to glucose, as described in section IC; the catalytic domains of section ID can be used to catalyze the linkage of N-acetylglucosamine and N-acetylglucosamine, N-acetylgalactosamine to N-acetylglucosamine, and mannose to N-acetylglucosamine; and the catalytic domains of section IE can be used to catalyze the linkage of a donor and an acceptor having a bulky side-group, such as linking galactose to N-acetylglucosamine-6-SO3.
  • Acceptors may be free in solution or linked to another molecule. For example, an acceptor may be linked to a protein, another sugar, a sugar derivative, and the like. An acceptor may also be linked to a solid support that provides a platform to which donors may be added sequentially to form oligosaccharides, and derivatives thereof, having a specified sequence.
  • Generally, the linkage between a donor and an acceptor is accomplished by incubating a catalytic domain of the invention with a desired donor and a desired acceptor under conditions of appropriate temperature, pH, and divalent metal concentration to allow linkage of the donor to the acceptor.
  • For example, the galactose and N-acetylgalactosyltransferase activity of β(1,4)-galactosyltransferase I can be determined using the following assay conditions. A 100 μl incubation mixture containing 50 mM β-benzyl-GlcNAc, 10 mM MnCl2, 10 mM Tris-HCl (pH 8.0), 500 μM UDP-Gal or UDP-GalNAc, and 20 ng of β(1,4)-galactosyltransferase I can be incubated at 37° C. for 10 minutes to promote coupling of a donor sugar to an acceptor sugar. While these conditions are provided as an example, it is understood that many other conditions may be used to chemically link a donor to an acceptor using the altered catalytic domains of the invention.
    • VI. Methods to Prepare Oligosaccharides.
  • The invention provides methods to synthesize oligosaccharides, especially oligosaccharides having preselected sequences though use of the altered catalytic domains of the invention. Generally, the methods involve the sequential addition of a sugar, or derivative thereof, to the end of a growing oligosaccharide chain. Such methods have been described using enzymes other than those of the invention (U.S. Pat. No. 6,284,493).
  • Briefly, a donor and an acceptor may be incubated with an altered catalytic domain of the invention under conditions that allow the donor to be linked to the acceptor. These conditions are described in the examples section herein.
  • In one example, the donor and the acceptor may be combined with a catalytic domain of the invention in solution. The solution is then incubated to allow the donor to be linked to the acceptor. The newly linked molecule may be isolated and then added to a second solution containing a second donor and a second transferase enzyme. This cycle may be repeated with a specific donor added at each cycle such that an oligosaccharide having a specific sequence is produced.
  • In another example, an acceptor may be linked to a solid support. The solid support may then be immobilized in a structure such as a column or a tray. A donor and a catalytic domain of the invention can then be incubated with the immobilized acceptor under conditions that allow the donor to be linked to the acceptor. The solid support is then washed to remove any unlinked donor and catalytic domain present. A second donor and a second transferase enzyme can then be added and incubated under conditions that allow the donor to be linked to the acceptor. This cycle can be repeated to allow for the rapid and large-scale production of oligosaccharides having defined sequences. In addition, this method may be readily adapted for use in an automated system. This system may be used without the need for protecting groups on the acceptor or the donor due to the use of enzymes that catalyze the linkage of a given donor to a given acceptor. Accordingly, an advantage of this method is that mild reaction conditions may be used that do not damage the growing oligosaccharide chain. Another advantage of the method is the short cycling time required to add monomers onto the growing oligosaccharide chain due to the lack of a need to protect and deprotect the growing oligosaccharide chain.
  • Other methods for using the catalytic domains of the invention to synthesize sequences of predetermined oligosaccharides and derivatives thereof may also be used. However, these methods will utilize an galactosyltransferase having an altered acceptor site, an altered donor site, or altered donor and acceptor sites.
    • VII. Methods to Increase the Immunogenicity of an Antigen.
  • The invention provides methods to increase the immunogenicity of an antigen. Generally, the methods involve incubating an antigen with a catalytic domain of the invention such that a sugar is transferred from a donor to an acceptor through the action of a catalytic domain.
  • The methods of the invention may be used in association with nearly any acceptor containing material against which an immune response is desired. For example, sugars may be transferred from a donor to an acceptor that is linked to a whole cell. The cell can then be killed through irradiation or chemical means and administered to an animal to elicit an immune response. Cell membranes may be used in a similar manner. Methods to create an immune response against cells and cell membranes are described in U.S. Pat. No. 6,361,775.
  • The immunogenicity of a virus or subunit thereof may be increased according to the methods of the invention and used as an improved vaccine. For example, for a virus that contains a glycoprotein as a component of the virion, one or more sugars may be added to the glycoprotein by propagation of the virus in a cell that expresses a catalytic domain of the invention. Alternatively, one or more sugars may be directly added to the glycoprotein using a catalytic domain of the invention. Furthermore, there exist viruses without envelopes that contain complex carbohydrates. Sugars may be added onto these carbohydrates through use of a catalytic domain of the invention.
  • Viral subunits may be obtained from virions using biochemical methods or they can be expressed by recombinant means in suitable eukaryotic cells. Methods of expressing viral subunits are common in the art. These methods may vary according to the type of virus used. For example, methods of expressing viral subunits are described in the following articles and in the references cited therein: Possee, Virus Research. 5:43 (1986); Kuroda et al., EMBO J., 5: 1359 (1986); Doerfler, Curr. Topics Microbiol. Immunol., 131:51 (1986); Rigby, J. Gen. Virol. 64:255 (1983); Mackett et al., In: DNA Cloning, A Practical Approach, Vol II, Ed. D. M. Glover, IRL Press, Washington, D.C. (1985); Rothestein, In: DNA Cloning, A Practical Approach, Supra (1985); Kinney et al., J. Gen. Virol. 69:3005 (1988); Panical et al., Proc. Natl. Acad. Sci., 80:5364 (1983); Small et al., In: Vaccinia Viruses as Vectors for Vaccine Antigens, pp. 175-178, Ed. J. Quinnan, Elsevier, N.Y (1985).
  • Viruses for which vaccines are currently available and whose immunogenicity can be improved according to the methods of the invention include influenza virus (Orthomyxovirus); rabies virus (Rhabdovirus); hepatitis B virus (Hepadnavirus); eastern, western and Venezuelan equine encephalitis virus (Togavirus/Alphavirus genus); and, Japanese encephalitis virus, tick-borne encephalitis virus and Russian spring-summer encephalitis virus (Flavivirus); Rift Valley fever virus (Bunyavirus) (reviewed: Melnick, In: High Technology Route to Virus Vaccines Ed. Dreesman, Bronson and Kennedy, American Society for Microbiology, Washington, D.C. (1985); Ogra et al., Prog. Med. Virol., 37:156 (1990)). Viruses for which vaccines are not yet commercially available but which may also be useful when treated according to the methods of the invention include, but are not limited to human immunodeficiency and human T-cell leukemia viruses (Retrovirus); respiratory syncytial virus and other paramyxoviruses (Paramyxovirus); herpes simplex viruses types 1 and 2, varicella zoster virus, cytomegalovirus and other herpes viruses (Herpesviruses); dengue virus and Saint Louis encephalitis virus (Flavivirus); hantaan virus (Bunyavirus); Lassa virus (Arenavirus); and, rotavirus (Reovirus). In addition, there exist viral vaccines comprising live attenuated viruses the administration of which to humans is associated with some measure of risk of mild to severe side effects. It is now possible according to the methods of the invention to enhance the immunogenicity of killed virus vaccines which may serve to reduce the use of their live, more risk-associated counterparts. Thus, vaccines which currently comprise live virus, such as measles virus, mumps virus, rubellavirus etc. are all encompassed by the invention.
  • Vaccines are prepared by suspension of a suitable concentration of an antigen that has been linked to a sugar, through the action of a catalytic domain of the invention, in a pharmaceutically acceptable carrier. The composition of the carrier will depend upon the type of vaccine and the route of administration and will be readily apparent to one skilled in the art. The vaccine may be administered in a dose of 102 to 109 cells per dose (in the case of whole cells) or a similar equivalent of cell membranes. In the case of viral vaccines, virus may be administered in dose ranging from 1 μg to 50 mg of virus per dose, or a similar equivalent of subunit. Determination of the appropriate dosage of vaccine will be apparent to one of skill in the art and will depend upon the antigens comprising the vaccine, the age of the patient and their general and immunological health.
  • In order to improve the efficacy of vaccines prepared according to the methods of the invention, patients may be pretreated with adjuvant at the site of vaccination several days prior to administration of vaccine. Pretreatment with adjuvant serves to induce migration of macrophages to the site of inoculation, thereby enhancing the rate of phagocytosis of treated antigens. In the case of viral vaccines, patients may be treated with adjuvant and vaccine simultaneously. Adjuvants suitable for this purpose include aluminum hydroxide and like adjuvants.
  • Vaccines are administered to a mammal, particularly a human, either subcutaneously, intramuscularly, orally, intravenously, intradermally, intranasally or intravaginally. Prior to oral administration, the vaccine can be mixed with a solution containing a sufficient amount of sodium bicarbonate or other suitable compound capable of neutralizing stomach acid (approximately 2 grams). Alternatively, the vaccine usually in lyophilized form, can be formulated as tablets which are treated with a coating capable of resisting stomach acid.
  • TABLE I
    Exemplary Amino Acid Sequences
    SEQ
    ID Accession
    NO Number Description Amino Acid Sequence
    3 BAA06188 Human MRLREPLLSRSAAMPGASLQRACRLLVAVCA
    β(1,4)galactosyl- LHLGVTLVYYLAGRDLSRLPQLVGVSTPLQG
    transferase GSNSAAAIGQSSGDLRTGGARPPPPLGASSQ
    (398 AA) PRPGGDSSPVVDSGPGPASNLTSVPVPHTTA
    LSLPACPEESPLLVGPMLIEFNMPVDLELVA
    KQNPNVKMGGRYAPRDCVSPHKVAIIIPFRN
    RQEHLKYWLYYLHPVLQRQQLDYGIYVINQA
    GDTIFNRAKLLNVGFQEALKDYDYTCFVFSD
    VDLIPMNDHNAYRCFSQPRHISVAMDKFGFS
    LPYVQYFGGVSASSKQQFLTINGFPNNYWGW
    GGEDDDIFNRLVFRGMSISRPNAVVGTCRMI
    RHSRDKKNEPNPQRFDRIAHTKETMLSDGLN
    SLTYQVLDVQRYPLYTQITVDIGTPS
    4 A33396 Mouse MRFREQFLGGSAAMPGATLQRACRLLVAVC
    β(1,4)galactosyl- ALHLGVTLVYYLSGRDLSRLPQLVGVSSTLQ
    transferase GGTNGAAASKQPPGEQRPRGARPPPPLGVSP
    (399 AA) KPRPGLDSSPGAASGPGLKSNLSSLPVPTTT
    GLLSLPACPEESPLLVGPMLIDFNIAVDLEL
    LAKKNPEIKTGGRYSPKDCVSPHKVAIIIPF
    RNRQEHLKYWLYYLHPILQRQQLDYGIYVIN
    QAGDTMFNRAKLLNIGFQEALKDYDYNCFVF
    SDVDLIPMDDRNAYRCFSQPRHISVAMDKFG
    FSLPYVQYFGGVSALSKQQFLAINGFPNNYW
    GWGGEDDDIFNRLVHKGMSISRPNAVVGRCR
    MIRHSRDKKNEPNPQRFDRIAHTKETMRFDG
    LNSLTYKVLDVQRYPLYTQITVDIGTPR
    5 S05018 Bovine MKFREPLLGGSAAMPGASLQRACRLLVAVC
    β(1,4)galactosyl- ALHLGVTLVYYLAGRDLRRLPQLVGVHPPLQ
    transferase GSSHGAAAIGQPSGELRLRGVAPPPPLQNSS
    (402 AA) KPRSRAPSNLDAYSHPGPGPGPGSNLTSAPV
    PSTTTRSLTACPEESPLLVGPMLIEFNIPVD
    LKLIEQQNPKVKLGGRYTPMDCISPHKVAII
    ILFRNRQEHLKYWLYYLHPMVQRQQLDYGIY
    VINQAGESMFNRAKLLNVGFKEALKDYDYNC
    FVFSDVDLIPMNDHNTYRCFSQPRHISVAMD
    KFGFSLPYVQYFGGVSALSKQQFLSINGFPN
    NYWGWGGEDDDIYNRLAFRGMSVSRPNAVIG
    KCRMIRHSRDKKNEPNPQRFDRIAHTKETML
    SDGLNSLTYMVLEVQRYPLYTKITVDIGTPS
    6 Human RDLSRLPQLVGVSTPLQGGSNSAAAIGQSSG
    Stem Region of DLRTGGARPPPPLGASSQPRPGGDSSPVVDS
    β(1,4)galactosyl- GPGPASNLTSVPVPHTTALSLPACPEESPLL
    transferase VGPMLIEFNMPVDLELVAKQ
    7 Bovine RDLRRLPQLVGVHPPLQGSSHGAAAIGQPSG
    Stem Region of ELRLRGVAPPPPLQNSSKPRSRAPSNLDAYS
    β(1,4)galactosyl- HPGPGPGPGSNLTSAPVPSTTTR
    transferase
    8 Human Catalytic SLPACPEESPLLVGPMLIEFNMPVDLELVAK
    Domain of QNPNVKMGGRYAPRDCVSPHKVAIIIPFRNR
    β(1,4)galactosyl- QEHLKYWLYYLHPVLQRQQLDYGIYVINQAG
    transferase DTIFNRAKLLNVGFQEALKDYDYTCFVFSDV
    DLIPMNDHNAYRCFSQPRHISVAMDKFGFSL
    PYVQYFGGVSASSKQQFLTINGFPNNYWGWG
    GEDDDIFNRLVFRGMSISRPNAVVGTCRMIR
    HSRDKKNEPNPQRFDRIAHTKETMLSDGLNS
    LTYQVLDVQRYPLYTQITVDIGTPS
    9 Bovine Catalytic SLTACPEESPLLVGPMLIEFNIPVDLKLIEQ
    Domain of QNPKVKLGGRYTPMDCISPHKVAIIILFRNR
    β(1,4)galactosyl- QEHLKYWLYYLHPMVQRQQLDYGIYVINQAG
    transferase ESMFNRAKLLNVGFKEALKDYDYNCFVFSDV
    DLIPMNDHNTYRCFSQPRHISVAMDKFGFSL
    PYVQYFGGVSALSKQQFLSINGFPNNYWGWG
    GEDDDIYNRLAFRGMSVSRPNAVIGKCRMIR
    HSRDKKNEPNPQRFDRIAHTKETMLSDGLNS
    LTYMVLEVQRYPLYTKITVDIGTPS
  • TABLE II
    Exemplary Nucleic Acid Sequence
    SEQ
    ID Accession
    NO Number Description Nucleic Acid Sequence
    10 D29805 Human ATGAGGCTTCGGGAGCCGCTCCTGAGCCGGA
    β3(1,4)galactosyl- GCGCCGCGATGCCAGGCGCGTCCCTACAGCG
    transferase GGCCTGCCGCCTGCTCGTCGCCGTCTGCGCT
    CTGCACCTTGGCGTCACCCTCGTTTACTACC
    GCTGGCCGCGACCTGAGCCGCCTGCCCCAAC
    TGGTCGGAGTCTCCACACCGCTGCAGGGCGG
    GTCGAACAGTGCCGCCGCCATCGGGCAGTCC
    TCCGGGGACCTCCGGACCGGAGGGGCCCGGC
    CGCCGCCTCCTCTAGGCGCCTCCTCCCAGCC
    GCGCCCGGGTGGCGACTCCAGCCCAGTCGTG
    GATTCTGGCCCTGGCCCCGCTAGCAACTTGA
    CCTCGGTCCCAGTGCCCCACACCACCGCACT
    GTCGCTGCCCGCCTGCCCTGAGGAGTCCCCG
    CTGCTTGTGGGCCCCATGCTGATTGAGTTTA
    ACATGCCTGTGGACCTGGAGCTCGTGGCAAA
    GCAGAACCCAAATGTGAAGATGGGCGGCCGC
    TATGCCCCCAGGGACTGCGTCTCTCCTCACA
    AGGTGGCCATCATCATTCCATTCCGCAACCG
    GCAGGAGCACCTCAAGTACTGGCTATATTAT
    TTGCACCCAGTCCTGCAGCGCCAGCAGCTGG
    ACTATGGCATCTATGTTATCAACCAGGCGGG
    AGACACTATATTCAATCGTGCTAAGCTCCTC
    AATGTTGGCTTTCAAGAAGCCTTGAAGGACT
    ATGACTACACCTGCTTTGTGTTTAGTGACGT
    GGACCTCATTCCAATGAATGATCATAATGCG
    TACAGGTGTTTTTCACAGCCACGGCACATTT
    CCGTTGCAATGGATAAGTTTGGATTCAGCCT
    ACCTTATGTTCAGTATTTTGGAGGTGTCTCT
    GCTTCAAGTAAACAACAGTTTCTAACCATCA
    ATGGATTTCCTAATAATTATTGGGGCTGGGG
    AGGAGAAGATGATGACATTTTTAACAGATTA
    GTTTTTAGAGGCATGTCTATATCTCGCCCAA
    ATGCTGTGGTCGGGACGTGTCGCATGATCCG
    CCACTCAAGAGACAAGAAAAATGAACCCAAT
    CCTCAGAGGTTTGACCGAATTGCACACACAA
    AGGAGACAATGCTCTCTGATGGTTTGAACTC
    ACTCACCTACCAGGTGCTGGATGTACAGAGA
    TACCCATTGTATACCCAAATCACAGTGGACA
    TCGGGACACCGAGCTAG
    • Example 1 General Expression, Mutagenesis, Folding, and Purification of Catalytic Domains of Bovine β(1,4)-galactosyltransferase I Materials and Methods
  • Bacterial growth and plasmid transformations were performed using standard procedures (Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley-Interscience, New York (1987)). The plasmid pEGT-d129, which encodes the catalytic domain (residues 130-402) of bovine β(1,4)-galactosyltransferase I, was used for mutation. Site-directed mutagenesis was performed using a CLONTECH site-directed mutagenesis transformer kit. The transformation mixture contained the template pEGT-d129, a selection primer, and a mutagenic primer for creation of a desired mutant. Mutants were screened for the incorporated mutations by looking for changes in restriction enzyme digestion patterns and confirmed by DNA sequencing. The positive clones were transformed into B834(DE3)pLysS cells. The primers were synthesized by the Molecular Technology Laboratory, NCI-Frederick.
  • The expression and purification of the inclusion bodies were carried out as described previously (Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley-Interscience, New York (1987)). The inclusion bodies were S-sulfonated by dissolving in 5 M GdnHCl, 0.3 M sodium sulfite, and the addition of di-sodium 2-nitro-5-thiosulfobenzoate to a final concentration of 5 mM. The sulfonated protein was precipitated by dilution with water, and the precipitate was washed thoroughly.
  • The sulfonated protein was re-dissolved in 5 M GdnHCl to a protein concentration of 1 mg/ml (1.9-2.0 optical density at 275 nm). The protein solution was diluted 10-fold, in 10 portions, in a folding solution to give a final concentration of 100 μg/ml β(1,4)-galactosyltransferase I, 0.5 M GdnHCl, 50 mM Tris-HCl, 5 mM EDTA, 4 mM cysteamine, and 2 mM cystamine, pH 8.0 at 4° C. It was left at 4° C. for 48 h to allow the protein to fold and then dialyzed against 3×4 liters of water containing 50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 4 mM cysteamine, and 2 mM cystamine at 4° C. to remove GdnHCl. Any protein that precipitated during dialysis was removed by centrifugation, and the supernatant was concentrated. Typically, when 100 mg of sulfonated protein was folded in a 1-liter folding solution, it yields 2-5 and 10-12 mg of the active, soluble, and pure wild-type β(1,4)-galactosyltransferase I catalytic domain, or mutant thereof. The folded proteins were purified further on an LA-agarose column (Sigma). The final, purified protein had a specific activity that was slightly higher than that of purified milk β(1,4)-galactosyltransferase I.
  • Site-directed Mutagenesis of amino acid position 289 of the bovine β(1,4)-galactosyltransferase I: Site-directed mutagenesis was performed using the PCR method. Construction of the mutants was done using plasmid pEGT-d129 as the template; this contains a BamH1/EcoRI fragment inserted into pEGT23a vector, coding for the residues 130-402 of bovine β(1,4)-galactosyltransferase I, and has a Cys-342 to Thr mutation.
  • The mutation primers corresponding to the upper DNA strand are: Y289L, 5′-CCTTACGTGCAATTGTTTGGAGGTGTCTCTGCTCTAAGTAAA-3′ (SEQ ID NO: 11) and 5′-GACACCTCCAAACAATTGCACGTAAGGTAGGCTAAA-3′ (SEQ ID NO: 12); Y289I, 5′-CTACCTTACGTGCAGATCTTTGGAGGTGTCTCTGCTCTAAG-3′ (SEQ ID NO: 13) and 5′-GACACCTCCAAAGATCTGCACGTAAGGTAGGCTAATCCAA-3′ (SEQ ID NO: 14); Y289N, 5′-GGATTAGCCTACCATATGTGCAGAATTFTGGAGGTGTCTCT-3′ (SEQ ID NO: 15) and 5′-AGAGACACCTCCAAAATTCTGCACATCTGGTAGGCTAAATCC-3′ (SEQ ID NO: 16). Typically, the entire Gal-T1 DNA was PCR-amplified as two fragments using the terminal cloning primers and two mutagenesis primers. The fragments were then cut with the restriction enzymes MfeI, BglII, and NdeI for Y289L, Y286I, and Y286N mutants, respectively, and ligated. The full Gal-T1 DNA with the mutation was amplified from the ligation mixture using the cloning primers and then inserted into the pET28a vector. Mutants were screened for the incorporated mutations, based on alterations in the restriction enzyme digestion patterns, and then sequenced. The positive clones were transformed into B834(DES)pLys8 cells as described previously (Ramakrishnan et al., J. Biol. Chem., 270, 87665-376717 (2001)). The mutant proteins were expressed and purified according to the published method (Ramakrishnan et al., J. Biol. Chem., 270, 87665-376717 (2001)).
  • Gal-T and GalNAc-T Enzyme Assays: The protein concentrations were measured using the Bio-Rad protein assay kit, based on the method of Bradford and further verified on SDS gel. An in vitro assay procedure for the Gal-T1 has been reported previously (Ramakrishnan et al., J. Biol. Chem., 270, 87665-376717 (2001)). The activities were measured using UDP-Gal or UDP-GalNAc as sugar nucleotide donors, and GlcNAc and Glc as the acceptor sugars. For the specific activity measurements, a 100-μl incubation mixture containing 50 mM β-benzyl-GlcNAc, 10 mM MnCl2, 10 mM Tris-HCl, pH 8.0, 500 μM UDP-Gal or UDP-GalNAc, 20 ng of Gal-T1, and 0.5 μCl of [3H]UDP-Gal or [3H]UDP-GalNAc was used for each Gal-T or GalNAc-T reaction. The incubation was carried out at 37° C. for 10 min. The reaction was terminated by adding 200 μl of cold 50 mM EDTA, and the mixture was passed through a 0.5-ml bed volume column of AG1-X8 cation resin (Bio-Rad) to remove any unreacted [3H]UDP-Gal or [3H]UDP-GalNAc. The column was washed successfully with 300, 400, and 500 μl of water, and the column flow-through was diluted with Biosafe scintillation fluid; radioactivity was measured with a Beckman counter. A reaction without the acceptor sugar was used as a control. A similar assay was carried out to measure the GalNAc-T activity with Glc and other acceptors in the presence of 50 μM bovine LA (Sigma).
  • Studies for Determining the Kinetic Constants: The true Km of the donor (KA) and of the acceptor (KB), the dissociation constant of the donor, Ki(a), and kcat were obtained using two-substrate analyses and the primary plots of five concentrations of donor (UDP-Gal or UDP-GalNAc) and five concentrations of acceptor, and the corresponding secondary plots of the intercepts and slopes. Initial rate conditions were linear with respect to time. A suitable range of donor and acceptor concentrations were chosen, which allowed an accurate Michaelis-Menten plot to be derived. The data were also analyzed for a general two-substrate system using the following equations (Zhang et al., Glycobiology, 9:815-822 (1999)) with the software EnzFitter, a Biosoft nonlinear curve-fitting program for Windows.
  • v = V max [ A ] [ B ] K i ( a ) K B + K A [ A ] + K B [ B ] + [ A ] [ B ] Equation 1 v = V max [ A ] [ B ] K A [ A ] + K B [ B ] + [ A ] [ B ] Equation 2
  • Here v is the initial velocity and the rate equation for sequential symmetrical initial velocity pattern associated with Equation 1, an ordered or random equilibrium mechanism in which substrate A dissociates well from the E-S complex with a dissociation constant of Ki(a). Equation 2 is for asymmetric initial velocity pattern for a double displacement or “ping-pong” mechanism. The kinetic parameters KA, KB, Ki(a), and Vmax, were obtained from the fitted curves using the above rate equations. The graphical method and EnzFitter program gave very similar kinetic parameters. In the N-acetylgalactosamine transferase (GalNAc-T) assay, the maximum substrate concentrations used for UDP-GalNAc and GlcNAc were 1 and 200 mm, respectively. However, in the galactose transferase (Gal-T) assay, because of the limited solubility of GlcNAc in water, the concentration of GlcNAc was limited to no more than 400 mM (which is 2-fold higher than its Km value), whereas up to 300 μM UDP-Gal were used.
  • 1H NMR Spectroscopy of the Products of GalNAc-T Activity: The reaction was carried out in a total volume of 1 ml that contained 100 μg of Y289L mutant plus 10 mM each triethanolamine-HCl, pH 8.0, UDP-GalNAc, GlcNAc, and MnCl2 at 37° C. for 48 h. The mixture was first passed through a 1-ml Chelex 100 column and then through a 1-ml cationic column containing AG1-X8 resin (200-400-mesh). The disaccharide product in the flow-through from 4 bed volumes was pooled and freeze-dried. The product was finally dissolved in 400 μl of D2O, and its 1H NMR spectrum was obtained in a 400-MHz NMR spectrometer. All the NMR spectra were recorded in the Analytical Chemistry Laboratory, NCI-Frederick (Frederick, Md.).
    • Results
  • Comparison of Gal-T and GalNAc-T Catalytic Activities of Wild-type and Gal-T1 Mutants: The mutants Y289L, Y289N, and Y289I exhibited both galactose transferase and N-acetylgalactosyltransferase activities (Table III and FIG. 1). The mutants Y289L and Y289N exhibited equally strong galactose transferase and N-acetylgalactosyltransferase activities. The specific N-acetylgalactosyltransferase activity of the mutant Y289I at the substrate concentration used was half that of Y289L (Table III). The Y289I mutant exhibited a slightly weaker affinity to UDP-GalNAc (FIG. 1). The Asn substitution exhibited GalNAc-T activity as well as the Leu substitution. Wild-type-Gal-T1 exhibits a very low glucosyltranferase activity, but no N-acetylglucosaminyltransferase activity (Berliner and Robinson, Biochemistry, 21:6840-68433 (1982); Palmin and Hindaganl, Glycobiology, 1:205-209 (1991); Ramakrishnan et al., J. Biol. Chem., 270:87665-37671 (2001)). On the contrary, the mutants exhibited reasonable N-acetylglucosaminyltransferase activity (Table III) where they transfer N-acetylglucosamine from UDP-N-acetylglucosamine to the acceptor N-acetylglucosamine but do not exhibit glucosyltranferase activity. In this N-acetylglucosaminyltransferase activity the initial product, the disaccharide GlcNAc β1,4-GlcNAc, itself is an acceptor for the enzyme, thus producing tri- and longer chain saccharides.
  • TABLE III
    Specific activities of the catalytic domain of Gal-T1 (residues
    130-402) with the C342T mutation and the Tyr-289 mutants
    UDP-galactose → GlcNAc UDP-GalNAc → GlcNAc UDP-GlcNAc → GlcNAc
    Gal-T activity GalNAc-T activity GlcNAc-T activity
    Enzyme pmol/min/ng pmol/min/ng pmol/min/ng
    C342T 11.8 0.1 0
    Y289L_C342T 16.2 27.3 8.2
    Y289I_C342T 8.8 14.7 6.2
    Reactions were performed under saturating conditions of all substrates (assay conditions are described herein). In these reactions, the concentration for the donors was 500 μM and the acceptor β-benzyl-GlcNAc was 25 mM. In the Gal-T reaction of C342T, the acceptor concentration was 10 mM, because at 25 mM it showed inhibition. Because Y289N rapidly undergoes denaturization, reliable data could not be obtained.
  • Because the Y289L variant of Gal-T1 exhibits both Gal-T and GalNAc-T enzyme activities with equal efficiencies, double substrate kinetic studies were carried out to determine the kinetic constants for both donor and acceptor molecules. The kinetic data from both reactions fit best to Equation 2, with a zero Ki(a) value, describing an asymmetric initial velocity pattern for a double-displacement or “ping-pong” mechanism. The Y289L mutant in the Gal-T reaction showed nearly a 20-fold higher Km for the acceptor than the wild-type Gal-T1 (Table IV). The catalytic constant (kcat) in the Gal-T1 reaction is comparable with the wild type, but it is nearly 3-5-fold higher in the GalNAc reaction (Table IV).
  • TABLE IV
    Kinetic parameters for the donor and the acceptor substrates by
    Y289L_C342T mutant in the Gal-T and the GalNAc-T catalytic reactions
    GalNAc-T UDP-N-
    Gal-T UDP-galactose → GlcNAc acetylgalactosamine → GlcNAc
    KA KB Kcat. KA KB Kcat.
    Mutant μM MM — μM mM —
    C342T 98 (6)  11(1) 14 ND ND ND
    Y289L_C342T 75 (1) 198(1) 8.5 854 (8) 51 (1) 4.0
    ND, not determined
  • Because the Y289L mutant exhibits equally high GalNAc-T activity as it does Gal-T activity, the disaccharide product from this reaction was purified and analyzed by 1H NMR spectroscopy (FIG. 4). The NMR results demonstrated that the mutant Y289L transfers GalNAc from UDP-GalNAc to GlcNAc, forming β1-4 linkage between GalNAc and GlcNAc.
  • A Point Mutation in the Codon for Amino Acid 289 Can Convert the Enzyme with Dual Property: In humans, the β4Gal-T family has seven members (Gal-T1 to -T7), each with high sequence identity within their catalytic domain (Lo et al., Glycobiology, 8:517-526 (1998); Nomura et al., J. Biol. Chem., 273:13570-13577 (1998)). These family members transfer Gal from UDP-Gal to different sugar acceptors. For example, Gal-T6 transfers Gal to Glc of Glc-ceramide, whereas Gal-T7 transfers Gal to xylose (Nomura et al., J. Biol. Chem. 273:13570-13577 (1998)). Among these seven members, four members, Gal-T1 to Gal-T4, have a Tyr residue at position 287 (which corresponds to Tyr-289 in bovine Gal-T1), whereas Gal-T5 and Gal-T6 have a Phe residue.
  • TABLE V
    Codon usage for the amino acid at position
    289 among the Gal-T1 family members
    Enzyme Codon Amino acid at position 289
    Bovine Gal-T1 TAT Tyr
    Human Gal-T1 TAT Tyr
    Human Gal-T2 TAC Tyr
    Human Gal-T3 TAC Tyr
    Human Gal-T4 TAT Tyr
    Human Gal-T5 TTT Phe
    Human Gal-T6 TTC Phe
    Human Gal-T7 TAC Tyr
    In human Gal-T1, the corresponding amino acid is at position 287. The second and third nucleotides of the codon show variations among the family members, while strictly conserving the first nucleotide. Mutation of the first nucleotide of the codon (shown in bold) to either A or C would result in a Leu or Asn residue instead of Tyr, and such a mutant would exhibit dual enzymatic activities.
  • Role of α-Lactalbumin (LA) in the GalNAc-T Activity of the wt-Gal-T1 and the Y289L Mutant: LA enhances the transfer of GalNAc from UDP-GalNAc to GlcNAc by Gal-T1 with ˜0.1% of its Gal-T efficiency, a situation similar to glucosyltransferase activity (Glc-T) of Gal-T1, where LA increases this activity from 0.3 to 10% (Ramakrishnan et al., J. Biol. Chem., 270:87665-37671 (2001)). LA plays a kinetics role in stimulating Gal-T1 to transfer Glc from the UDP-Glc to GlcNAc (Ramakrishnan et al., J. Biol. Chem., 270:87665-37671 (2001); Ramakrishnan et al., Biochem Biophys. Res. Commun., 291:1113-1118 (2002)). The activity is enhanced by approximately 1%. This level of activity was determined using the donor concentration of the unlabeled UDP-sugar, and only a small amount of 3H-labeled UDP-sugar. Use of this protocol allowed for accurate calculation based on the amount of unlabeled UDP-sugar used.
  • Unlike wt-Gal-T1, where LA stimulates the transfer of GalNAc only to GlcNAc and not to Glc (Do et al., Biol. Chem., 276:18447-18451 (1995)), the Tyr-289 mutants (Y289L, Y289N, and Y289I) in the presence of LA transfer GalNAc preferably to Glc rather than to GlcNAc. This property is quite similar to LS activity in which the wt-Gal-T1 in the presence of LA transfers Gal to Glc instead to GlcNAc (Table VI). Furthermore, like wt-Gal-T1, these mutants also transfer Gal to Glc in the presence of LA. For example, the N-acetylgalactosaminyltransferase activity in the bovine mammary gland extracts with a similar catalytic property has been identified (Van den Nieuwenhof et al., FEBS Lett., 459:377-380 (1999)). This enzyme also transfers GalNAc from UDP-GalNAc to GlcNAc in the absence of LA, whereas in the presence of LA it transfers GalNAc to Glc instead to GlcNAc.
  • TABLE VI
    GalNAc-T catalytic activity of Y289L mutant in the absence
    and the presence of LA on various acceptor substrates
    GalNAc-T activity
    −LA +LA
    Acceptor pmol/min/ng
    GlcNAc 31.3 3.3
    Glc 2.6 34.8
    Glucosamine 1.8 5.0
    Assays were carries out at 37° C. using 500 μM UDP-GalNAc for 10 minutes. In all the measurements, the acceptor concentration was 100 mM and the LA concentration was 55 μm.
  • It is shown herein that the Tyr-289 mutants of Gal-T1 exhibit as high GalNAc-T activity as Gal-T activity, as well as GlcNAc-T activity. In the human Gal-T family members, the Tyr/Phe residue at 287 (or in bovine Tyr-289) is important for determining the donor sugar specificity of the enzyme.
    • Example II General Expression, Mutagenesis, Folding, and Purification of Catalytic Domains of β(1,4)-galactosyltransferase I Enzymes Having an N-Terminal Stem Region Materials and Methods
  • Restriction endonucleases and DNA-modifying enzymes were from New England Biolabs (Beverly, Mass.). Oligonucleotide primers were synthesized by the Recombinant DNA Facility at NCI-Frederick. The plasmid mini preparation kit was from Qiagen (Santa Clarita, Calif.). Ampicillin, UDP-Gal and UDP-agarose were from Sigma Chemical Co, MO. pET23a vector and BL21 (λDE3)/pLysS competent cells were from Novagen (Madison, Wis.). E. coli XL2-Blue ultracompetent cells were from Stratagene (La Jolla, Calif.). AG1-X8 resin, chloride form, 200-400 mesh was from Bio-Rad (Hercules, Calif.). Taq DNA polymerase and PCR nucleotide mixes were obtained from Boehringer Mannheim.
  • Cloning of Bovine and Human Stem-CD Clones of β1,4-galactosyltransferase:
  • Two sets of oligonucleotide primers with unique restriction sites added at the 5′ (SR) and 3′ (CD) ends were synthesized based upon the bovine β4Gal-T1 and human β4Gal-T1 cDNA sequence (shown in FIGS. 3A and 3B). A full-length bovine cDNA clone encoding β4Gal-T1 was used for site-directed mutagenesis (Boeggeman et al., Protein Eng. 6:779-785 (1993)). In the stem region of bovine β4Gal-T1 Ser96 was mutated to Ala96 (described below). The mutated full-length cDNA template was amplified by the polymerase chain reaction (PCR), using the following primer pair to generate SRCDβ4Gal-T1:
  • (SEQ ID NO: 17)
    (SR) 5′-CGCGGATCCCGCGACCTAAGACGCCTGCCTCAGCTGGTC-3′
    and
    (SEQ ID NO: 18)
    (CD) 5′-TGGAATTCCTAGCTCGGCGTCCCGATGTCCACTGTGAT-3′.

    Human placental QUICK-Clone cDNA (Lot #9020891) was obtained from Clontech and used as the template for PCR. To amplify human β4Gal-T1 the following PCR primers were used:
  • (SEQ ID NO: 19)
    (SR) 5′-CGCGGATCCCGCGACCTGAGCCGCCTGCCCCAACTGGTC-3′
    and
    (SEQ ID NO: 20)
    (CD) 5′-CCGGAATTCCTACTAGCTCGGTGTCCCGATGTCCACTGT-
    3′.

    The primer pairs amplified the cDNA region that has both the stem and catalytic domain, and were designed to generate DNA fragments containing a Bam HI (SR) and Eco RI (CD) (underlined) at the 5′ and 3′-ends of the inserts, respectively. The PCR products were purified using a QLAquick PCR purification kit and the purified fragments were digested with Bam HI and Eco RI to generate the cohesive ends. The expression constructs were obtained after ligating the digested and gel-purified PCR fragments into the Bam HI and Eco RI-digested pET23a vector (Novagen, Madison, Wis.) and transformed into XL2-ultracompetent cells. Identities of the clones were confirmed by DNA sequence.
  • Mutation of the stem region of bovine β4Gal-T1 to inhibit proteolysis: The wild-type bovine SRCDβ4Gal-T1, which has Ser at position 96, was expressed in E. coli. Its sequence is shown in FIG. 3A. The recombinant wild-type protein folded and purified from inclusion bodies, as described below, was cleaved within the SR region, over a short period of time. The cleaved protein on SDS-PAGE shows a single band of molecular mass of 34.9 kDa. The protein was electroblotted to polyvinylidene difluoride membrane, and the N-terminal sequence of the cleaved fragment was determined by Edman degradation at the Protein Chemistry Laboratory, NCI-Frederick. The N-terminal sequence of the fragment was determined as SRAPSNLD (SEQ ID NO: 21). This corresponds to the cleavage at Ser96 within the sequence region KPR96SRAPSNLD (SEQ ID NO: 22). To prevent this proteolytic digestion within the stem region, we now constructed a mutant substituting Ala in place of Ser96. This prevented the cleavage within the stem region of bovine β4Gal-T1 keeping the recombinant protein intact for a long period of time. Even though, the experimental results described in this study are with the mutant bovine S96A-SRCDβ4Gal-T1 (FIG. 3A), for the sake of convenience in abbreviation this protein is simply referred to as bovine SRCDβ4Gal-T1. The human SRCDβ4Gal-T1 also gets cleaved within the stem region, at Val53 in the sequence QLV53GVSTPLQ (SEQ ID NO: 23), but only after long periods of time. Since this clone showed more stability than the bovine β4Gal-T1, it was not mutated and used as such for subsequent analysis.
  • Protein expression in E. coli and inclusion body isolation: For protein expression BL21 (λDE3)/pLysS-competent cells were transformed with the pET vector derivatives according to the manufacturer's protocols. The transformed cells were grown in LB broth containing 50 μg.ml−1 ampicillin to an OD600 nm of ˜0.7, followed by induction with 0.4 mM IPTG. Cultures were harvested after 3-4 hours by centrifugation at 2000×g for 20 min. The inclusion bodies were isolated and solubilized as described (Boeggeman et al., Protein Eng., 6:779-785 (1993)). From a liter of induced bacterial culture, the yield is generally 80 to 100 mg of purified inclusion bodies. Novex gels were used for SDS-PAGE analysis and the protein bands were visualized with Coomassie blue. Protein concentrations were measured with the Bio-Rad protein dye reagent with bovine serum albumin as the standard.
  • In vitro folding of proteins from inclusion bodies: A protocol utilizing oxido-shuffling agents within the renaturation buffer was used to generate active recombinant β4Gal-T1 from the inclusion bodies (Boeggeman et al., Protein Eng., 6:779-785 (1993)). After renaturation and subsequent dialysis of the solution, a portion of the folded protein precipitated in the form of insoluble aggregates. To increase the yields of native proteins, the inclusion bodies were sulfonated as previously described (Boeggeman et al., Glycobiology 12:395-407 (2002)). The sulphonated proteins were dissolved in 5 M guanidine-HCl, to a protein concentration of 1 mg/ml, with an OD275 nm of 1.9 to 2.0. The protein solution was then diluted 10-fold in small aliquots in a renaturation solution to give a final protein concentration of 100 μg/ml, in 50 mM Tris-HCl pH 8.0, 5 mM EDTA, 0.5 M guanidine-HCl, 8 mM cysteamine and 4 mM cystamine. The protein was allowed to renature for 48 hrs at 4° C. and then dialyzed. The precipitate was removed by centrifugation at 5000 rpm and the supernatant concentrated using ultrafiltration membranes (Amicon, Inc., Beverly, Mass., USA).
  • Improving the folding conditions: In recent years factorial folding screens (Rudolph and Lilie, FASEB J., 10:40-56 (1996); Chen and Gouaux, Proc. Natl. Acad. Sci. 94:13431-13436 (1997); Armstrong et al., Prot. Sci., 8:1475-1483 (1999)) have been developed for examining the folding efficiencies of proteins from inclusion bodies. To improve the in vitro folding efficiency, 8 different folding conditions similar to the formulations described in the Foldlt Screen kit (Hampton Research, CA) with certain modifications were tested. Condition I: 50 mM Tris-HCl pH 8.0, 5 mM EDTA, 0.5 M guanidine-HCl, 8 mM cysteamine and 4 mM cystamine. Condition II: 55 Mes pH 6.5, 10.56 mM NaCl, 0.44 mM KCl, 2.2 mM MgCl2, 2.2 mM CaCl2, 0.5 M guanidine-HCl. Condition III: similar to condition II with respect to the buffer, pH, chaotrope and salt condition, but it had 0.055% PEG-4000, 1.1 mM EDTA, 0.44 M sucrose and 0.55 M L-arginine. Condition IV: 55 mM Mes pH 6.5, 264 mM NaCl, 11 mM KCl, 0.055% PEG-4000, 0.5 M guanidine-HCl, 2.2 mM MgCl2, 2.2 mM CaCl2 and 0.44 M sucrose. Condition V: 55 mM Tris pH 8.2, 10.56 mM NaCl, 0.44 mM KCl, 1.1 mM EDTA, 0.44 M sucrose. Conditions VI and VIII are similar except for the presence of redox agents. Condition VII: 55 mM Mes pH 6.5, 264 mM NaCl, 11 mM KCl, 1.1 mM EDTA, 0.5 M guanidine-HCl, and 0.55 M L-arginine. The buffers II through VII had 100 mM GSH and 10 mM GSSG. Conditions I and VIII, had 8 mM cysteamine and 4 mM cystamine. Condition VIII, gave the highest enzymatic activity, soluble and folded protein, was 50 mM Tris-HCl pH 8.0, 10.56 mM NaCl, 0.44 mM KCl, 2.2 mM MgCl2, 2.2 mM CaCl2 0.5 M guanidine-HCl, 8 mM cysteamine and 4 mM cystamine, 0.055% PEG-4000 and 0.55 M L-arginine.
  • β4Gal-T1 Enzyme Assays: The in vitro assay for β4Gal-T1 enzyme activity was performed as described (Boeggeman et al., Glycobiology, 12:395-407 (2002)). The 3H-labeled-UDP-Gal was used as sugar donor and GlcNAc as the sugar acceptor. A reaction without GlcNAc was used as a control. The fusion SRCDβ4Gal-T1 proteins showed the same enzymatic activities when compared to the wild-type recombinant β4Gal-T1 (amount of product formation/min/mol of protein).
  • Binding of recombinant proteins to UDP-affinity column: UDP-agarose was used to bind the active proteins at 4° C. Columns containing 1 ml bed volume of UDP-agarose were pre-equilibrated with 10 ml of 25 mM cacodylic buffer, pH 7.6, containing 25 mM MnCl2. The renatured protein solutions (0.5 mg) were adjusted to the pre-equilibration buffer conditions and applied to the columns. After loading the sample, the pass-through was re-cycled. It was then analyzed for the unbound protein by SDS-PAGE. The columns were washed 3× with 1-ml portions of equilibration buffer. The bound protein was eluted with the elution buffer consisting of 25 mM cacodylic buffer, pH 7.6, 25 mM EDTA and 1 M NaCl. Fractions of 0.5 ml were collected from the columns, and aliquots were analysed by SDS-PAGE. For enzymatic analysis the appropriate fractions were pooled and dialysed against 50 mM Tris-HCl pH 8.0 at 4° C.
  • Circular dichroism-spectroscopy: Far ultraviolet circular dichroism spectra of recombinant proteins was measured in a JASCO J-715 spectropolarimeter. The spectra for each sample was scanned at a speed of 100 nm/min. Far ultraviolet circular dichroism spectra were obtained from 190 to 250 nm at room temperature using a pathlength of 0.1 mm with a 1.0 nm bandwidth. Protein was dissolved in Tris-HCl pH 8.0 at concentrations of 0.5 mg/ml. Buffer blanks obtained in the same cuvette were subtracted to generate net spectra. Raw ellipticity data were transformed into molar residue ellipticity using the concentration values determined from optical ultraviolet absorbance measurements. No smoothing or data averaging was applied.
    • Results Influence of the Stem Region (SR) Covalently Linked to the N-Termini of the Catalytic Domain (CD) of the β4Gal-T Family Members on the In Vitro Folding Efficiency of the Recombinant Proteins from Inclusion Bodies
  • The catalytic domain of β4Gal-T1 (amino acid residues 130-402) (sequence in FIG. 3A, SEQ ID NO: 9) accumulated as an insoluble material within the inclusion body fraction upon expression in E. coli. Essentially all the proteins with the stem regions covalently linked to the N-termini of the catalytic domain (sequence in FIG. 3A, SEQ ID NO: 9) also accumulated in the insoluble inclusion body fraction. Contaminating proteins from the inclusion bodies were removed by washing the insoluble pellet several times with a buffer containing 25% sucrose as described herein. The yield of the purified inclusion bodies, varied with the protein that is being expressed (Table VII). The proteins produced a single protein band of expected molecular size on SDS-PAGE gel (FIG. 4). These insoluble inclusion bodies required 5 M guanidine HCl for solubilization.
  • Sulphonation of the inclusion bodies of CDβ4Gal-T1 prior to the in vitro folding step gave higher yields of final folded proteins. The yield of sulphonated protein from the purified inclusion bodies was generally half of the starting protein material (Table VII). Oxido-shuffling reagents were present during the renaturation step to regenerate the enzyme activity from all the recombinant sulphonated proteins. The recombinant proteins having the stem region fused at the N-termini of the catalytic domain (SRCD) remained soluble during the renaturation step in 0.5 M guanidine HCl and the oxido-shuffling agents. Upon subsequent dialysis of the SRCD-protein solutions, to remove the guanidine HCl, both the folded and misfolded molecules remained soluble as judged by SDS-PAGE analysis. In contrast, a majority of the misfolded protein molecules aggregated and precipitated in the protein solution containing only the CD. The recovery of soluble human and bovine SRCDβ4Gal-T1 is 3- to 9-fold higher than proteins having only the CD domain following refolding in the absence of PEG-4000 and L-arginine. (Table VIII).
  • TABLE VII
    Yield of inclusion bodies and sulphonated proteins
    Amount of sulphonated
    Recombinant Inclusion protein recovered from
    Proteins body (mg)* inclusion bodies (mg)+
    Bovine CDβ4GalT-1 120 65
    Bovine SRCDβ4GalT-1 113 50
    Human CDβ4GalT-1 80 37
    Human SRCDβ4GalT-1 90 50
    *Amount of inclusion bodies obtained from the pellet of one liter of IPTG induced bacterial culture.
    +Amount of sulphonated protein was determined by SDS-PAGE and by protein estimation using the Bradford method (Bio Rad).
  • TABLE VIII
    In vitro renaturation of the sulphonated inclusion bodies
    −PEG/L-Arg+ +PEG/L-Arg+
    CDβ4Gal-T1 SRCDβ4Gal-T1 CDβ4Gal-T1 SRCDβ4Gal-T1
    mg (%)*{circumflex over ( )} mg (%)*{circumflex over ( )} mg (%)*{circumflex over ( )} mg (%)*{circumflex over ( )}
    Bovine 2.7 (14) 9.4 (47) 8.3 (42) 18.0  (90)
    Human 2.1 (11) 19.0 (95) 14.0 (69) 20.0 (100)
    +20 mg of sulphonated proteins were folded in the buffer previously described that does not contain PEG-4000 and L-arginine (condition I) (Boeggeman, et al.). The proteins after the renaturation step were dialyzed, centrifuged and their concentration determined by SDS-PAGE and the Bradford method (BioRad)
    *Percentage recovery of the soluble protein after in vitro folding of 20 mg of sulphonated β4Gal-T1
    {circumflex over ( )}The soluble renatured CDβ4Gal-T1 protein contains almost all folded molecules, whereas the soluble renatured SRCDβ4Gal-T1 contains misfolded proteins that are removed on UDP-agarose columns (see Table IX)
  • Renaturation conditions that increase the folding efficiency and specific activity of β4Gal-T1: After folding the bovine wild-type CDβ4Gal-T1 in a renaturation buffer I (described herein), the misfolded proteins precipitated out during subsequent dialysis. In an attempt to increase the amount of the folded native protein during the renaturation step, various folding conditions consisting of seven different solutions were tested. The results were compared to the yields obtained according to condition I (FIG. 5). The tested inclusion bodies were dissolved in 5 M guanidine HCl to a final protein concentration of 1 mg/ml. Aliquots of 50 μl of the protein solution were added to 950 μl of the folding buffers in an eppendorf tube, mixed gently and incubated at 4° C. for times ranging from 4 hours to overnight. The folding buffers varied, (conditions I to VIII as disclosed herein) with respect to: pH from 6.5 (in conditions II, III, IV and VII), to 8.0 (in conditions V, VI, and VIII); cations (in conditions II, IV, VI and VIII) and chelators (conditions I, III, V and VII). Conditions VI, VII and VIII had polar additives (L-arginine). Conditions IV and V had non-polar additives, such as sucrose. Condition III had both sucrose and L-arginine. Some buffers also had PEG4000 (conditions III, IV, VI and VIII). The appropriate redox environment was created by the presence of 100 mM reduced (GSH) and 10 mM oxidized (GSSH) glutathione, except under conditions I and VIII which contained cysteamine (8 mM) and cystamine (4 mM).
  • After overnight incubation and dialysis against 1 mM Tris-HCl pH 8.0, samples were centrifuged and 5 μl of supernatant from each sample was tested for galactosyltransferase activity and compared with each other (FIG. 5). The results showed the highest activity under the buffer condition VI and VIII. Both of these had 0.55 M L-arginine and 0.055% PEG-4000 (FIG. 5). All folding conditions were tested in the presence of 30 mM lauryl maltoside, which appears to have a negative effect on the folding yields of the recombinant proteins, even in the presence of 0.55 M L-arginine and 0.055% PEG-4060. The inclusion of sucrose had an inhibitory effect (condition IV and V). No preference was observed for pH, salts, or cations within the conditions tested. The redox environment created by 8 mM cysteamine: 4 mM cystamine, (condition VIII), was preferred over 100 mM GSH: 10 mM GSSH (condition VI). Enzymatic assays (FIG. 5) revealed that the combination of L-arginine and PEG-4000 in condition VIII, increased the in vitro folding efficiency of the CD and SRCD proteins by about 7- and 3-fold, respectively, compared to condition I which did not contain PEG4000 and L-arginine.
  • Misfolded proteins in the renatured SRCDβGal-T1: Renatured proteins were analyzed on SDS-PAGE gels under native and reducing conditions to determine whether the renatured SRCDβ4Gal-T1 proteins were natively folded or misfolded. Analyses under native conditions, in the absence of β-mercaptoethanol (βME) and without boiling the samples, revealed that both bovine and human soluble SRCDβ4Gal-T1 proteins contained misfolded molecules that aggregated and remained at the top of the gel (FIG. 6 (−)). Under reducing conditions, using βME in the boiled samples, the misfolded molecules of both bovine and human soluble SRCDβ4Gal-T1 proteins did not appear on the top of the wells in SDS-PAGE and produced single protein bands of the expected sizes (35 kDa for bovine species and 34 kDa for human species) (FIG. 6 (+)).
  • Binding of recombinant proteins to affinity columns: Folded and active CDβ4Gal-T1 obtained from inclusion bodies bound to, and was eluted from, a UDP-column with 25 mM EDTA and 1M NaCl. Thus, binding of soluble renatured CD and SRCDβ4Gal-T1 proteins to UDP-agarose columns was tested. Native SDS gel analyses of the soluble renatured CDβ4Gal-T1 protein, without βME and boiling, showed that all of the soluble renatured CD protein was natively folded. The renatured SRCDβ4Gal-T1 proteins were then applied to a UDP-agarose column. Nearly all of the renatured SRCDβ4Gal-T1 proteins bound to, and eluted from, the UDP-agarose column (FIG. 7). The specific enzymatic activity of the SRCDβ4Gal-T1 protein (product formation/min/ng protein) before and after being passed through the UDP-agarose column was measured to determine if the soluble protein fraction of the renatured SRCDβ4Gal-T1 protein contained properly folded molecules (FIG. 8). Also, the samples were analyzed in the absence of βME and without boiling. When condition I was used to fold bovine- and human-SRCD proteins (FIG. 8A), the folded molecules that eluted with 25 mM EDTA and 1 M NaCl, (FIG. 8A (+)) had 2- and 6-fold higher specific activities (FIG. 8A, crossed-hatched bars), respectively, when compared to the protein before loading onto the affinity column (FIG. 8A, black bars). The renatured human SRCDβ4Gal-T1 sample showed more misfolded proteins compared to bovine SRCDβ4Gal-T1 (FIG. 8A, bovine versus human black bars). In contrast, folding according to condition VIII, that contains PEG-4000 and L-arginine (FIG. 8B), increased properly folded human SRCD compared to condition I (FIG. 8B vs FIG. 8A, black bars, human SRCD). Protein eluted from the UDP-column under condition VIII (FIG. 8B, cross bar) had ˜2-fold higher specific activity as compared to the proteins before being loaded on the affinity column (FIG. 8B, black bars). Although soluble, a portion of the protein in the SRCD samples is not folded to enable binding to UDP-agarose. The increased specific activity of the eluted proteins indicated the amount of misfolded molecules present in the sample before being bound to the UDP-agarose column. These results agreed with the observation that the misfolded proteins in the samples before being passed through the UDP-agarose columns also remained at the top of the wells in the SDS-PAGE gel (FIGS. 7B and C, lane U). The soluble bovine and human CDβ4Gal-T1 behaved the same way regardless of the buffer used for folding (condition I or VIII) (Table IX). The specific activity of bovine and human CDβ4Gal-T1 before and after binding on UDP-agarose columns did not change.
  • TABLE IX
    Binding of in vitro folded β4Gal-T1 to UDP-agarose column
    −PEG/L-Arg +PEG/L-Arg
    CDβ4Gal-T1 SRCDβ4Gal-T1 CDβ4Gal-T1 SRCDβ4Gal-T1
    % Input+ Output % Input+ Output Input+ Output % Input* Output %
    yield* mg mg yield* mg mg mg mg yield* mg mg yield*
    Bovine 2.7 2.7 (14) 9.4 7.5 8.3 8.3 (42) 18.0 10.0 (50)
    (38)
    Human 2.1 2.1 (11) 19.0 12.2 14.0 14.0 (69) 20.0 11.0 (55)
    (61)
    +The amount of soluble protein, recovered from 20 mg of sulphonated protein after in vitro folding, loaded on UDP-agarose columns.
    *Percentage of final protein yield from 20 mg of sulphonated inclusion bodies after in vitro folding and passing through the UDP-agarose column. All of the soluble folded CDβ4Gal-T1 proteins bind to and elute from the UDP-agarose columns. On the other hand, the soluble folded SRCDβ4Gal-T1 fraction contains misfolded proteins that do not bind to the UDP-agarose column.
  • Circular dichroism-spectra of recombinant β4Gal-T1: Circular dichroism experiments were done with purified β4Gal-T1 proteins to determine if the addition of the stem disturbed the overall secondary structure of β4Gal-T1. No significant differences in secondary structure relative to the wild-type CDβ4Gal-T1 were detected for the bovine or human proteins. All systems showed extrema of negative ellipticity between 250 and 200 nm. The circular dichroism-spectrum of the wild-type enzyme was highly reproducible and showed negative extrema at 208 and 220 nm indicative of α-helicity. There was a small change in ellipticity observed in the 200-210 nm region upon the addition of the stem in both bovine and human SRCD proteins.
  • All publications, patents and patent applications are incorporated herein by reference. While in the foregoing specification this invention has been described in relation to certain preferred embodiments thereof, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details described herein may be varied considerably without departing from the basic principles of the invention.

Claims (7)

1.-11. (canceled)
12. An isolated catalytic domain from a β(1,4)-galactosyltransferase I that can catalyze formation of a galactose-β(1,4)-N-acetylglucosamine-6-SO3 bond.
13. The catalytic domain of claim 12, wherein
(a) the catalytic domain has conservative amino acid exchanges at amino acid positions 279 and 280, or
(b) serine is exchanged for lysine at amino acid position 279, and threonine is exchanged for phenylalanine at amino acid position 280.
14.-51. (canceled)
52. A kit comprising packaging material, and a β(1,4)-galactosyltransferase I catalytic domain that: can catalyze formation of a galactose-β(1,4)-N-acetylglucosamine-6-SO3 bond.
53. The kit of claim 52, further comprising a donor.
54. The kit of claim 53, wherein the donor is selected from the group consisting of UDP-galactose, UDP-mannose, UDP-N-acetylglucosamine, UDP-glucose, GDP-mannose, UDP-N-acetylgalactosamine, UDP-glucuronic acid, GDP-Fucose, and CMP-N-acetylneuraminic acid.
US12/321,006 2003-01-10 2009-01-13 Catalytic domains of beta(1,4)-galactosyl transferase i having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use Abandoned US20090233345A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/321,006 US20090233345A1 (en) 2003-01-10 2009-01-13 Catalytic domains of beta(1,4)-galactosyl transferase i having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43929803P 2003-01-10 2003-01-10
US45025003P 2003-02-25 2003-02-25
PCT/US2004/000470 WO2004063344A2 (en) 2003-01-10 2004-01-09 CATALYTIC DOMAINS OF β/1,4)-GALACTOSYLTRANSFERASE I HAVING ALTERED DONOR AND ACCEPTOR SPECIFICITIES, DOMAINS THAT PROMOTE IN VITRO PROTEIN FOLDING, AND METHODS FOR THEIR USE
US11/178,230 US7482133B2 (en) 2003-01-10 2005-07-08 Catalytic domains of β(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use
US12/321,006 US20090233345A1 (en) 2003-01-10 2009-01-13 Catalytic domains of beta(1,4)-galactosyl transferase i having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/178,230 Division US7482133B2 (en) 2003-01-10 2005-07-08 Catalytic domains of β(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use

Publications (1)

Publication Number Publication Date
US20090233345A1 true US20090233345A1 (en) 2009-09-17

Family

ID=32718075

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/178,230 Expired - Lifetime US7482133B2 (en) 2003-01-10 2005-07-08 Catalytic domains of β(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use
US12/321,006 Abandoned US20090233345A1 (en) 2003-01-10 2009-01-13 Catalytic domains of beta(1,4)-galactosyl transferase i having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/178,230 Expired - Lifetime US7482133B2 (en) 2003-01-10 2005-07-08 Catalytic domains of β(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use

Country Status (6)

Country Link
US (2) US7482133B2 (en)
EP (1) EP1587919A4 (en)
JP (1) JP2006518192A (en)
AU (2) AU2004204463B2 (en)
CA (1) CA2510550A1 (en)
WO (1) WO2004063344A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004204463B2 (en) * 2003-01-10 2009-02-12 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Catalytic domains of beta(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use
WO2005051429A2 (en) * 2003-11-19 2005-06-09 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeted conjugates with a modified saccharide linker
WO2005056783A1 (en) * 2003-12-05 2005-06-23 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Catalytic domains of beta(1,4)-galactosyltransferase i having altered metal ion specificity
DK3438131T3 (en) 2006-02-10 2022-04-11 Life Technologies Corp OLIGOSACCHARIDE MODIFICATION AND LABELING OF PROTEINS
JP2009531289A (en) * 2006-02-10 2009-09-03 ライフ テクノロジーズ コーポレーション Method for modifying and labeling proteins with oligosaccharides
LT3912642T (en) * 2012-10-23 2023-07-25 Synaffix B.V. Modified antibody, antibody-conjugate and process for the preparation thereof
ES2759503T3 (en) 2013-05-02 2020-05-11 Glykos Finland Oy Conjugates of a glycoprotein or a glycan with a toxic payload
US9738726B2 (en) 2013-06-11 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HER2-specific monoclonal antibodies and conjugates thereof
WO2015057066A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
WO2015057063A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Modified glycoprotein, protein-conjugate and process for the preparation thereof
WO2015057065A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
EP3058083B1 (en) 2013-10-14 2018-04-11 SynAffix B.V. Modified glycoprotein, protein-conjugate and process for the preparation thereof
CN103849606B (en) * 2014-01-21 2016-02-10 南京农业大学 A kind of application of galactosyltransferase of orthomutation
WO2015112013A1 (en) 2014-01-24 2015-07-30 Synaffix B.V. Process for the attachment of a galnac moiety comprising a (hetero)aryl group to a glcnac moiety, and product obtained thereby
JP2017505770A (en) 2014-01-24 2017-02-23 シンアフィックス ビー．ブイ． Process for cycloaddition of (hetero) aryl 1,3-dipole compounds with (hetero) cycloalkynes
WO2017132298A1 (en) 2016-01-27 2017-08-03 Medimmune, Llc Methods for preparing antibodies with a defined glycosylation pattern
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
EP3494135A1 (en) 2016-08-02 2019-06-12 The United States of America, as represented by The Secretary, Department of Health and Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
US11236171B2 (en) 2016-12-21 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
US11891451B2 (en) 2017-05-11 2024-02-06 Vib Vzw Glycosylation of variable immunoglobulin domains
AU2018268970A1 (en) 2017-05-19 2019-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
WO2019006280A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. Human monoclonal antibodies specific for cd33 and methods of their use
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human mesothelin antibodies and uses in cancer therapy
WO2019126041A1 (en) 2017-12-18 2019-06-27 The General Hospital Corporation Glycoengineering
JP2021528406A (en) 2018-06-19 2021-10-21 グリコス バイオメディカル オーワイ Conjugate
EP3813883A1 (en) 2018-06-29 2021-05-05 Glykos Biomedical Oy Conjugates
CA3105694A1 (en) 2018-07-12 2020-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured cd22-specific monoclonal antibody and uses thereof
CA3106544A1 (en) 2018-08-08 2020-02-13 Mitchell Ho High affinity monoclonal antibodies targeting glypican-2 and uses thereof
JP2022506635A (en) * 2018-11-08 2022-01-17 カレイド・バイオサイエンシズ・インコーポレイテッド Oligosaccharide composition and its usage
WO2020146182A1 (en) 2019-01-08 2020-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross-species single domain antibodies targeting mesothelin for treating solid tumors
WO2020154150A1 (en) 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
AU2020370125A1 (en) 2019-10-22 2022-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting B7H3 (CD276) for treating multiple solid tumors
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
WO2021123506A1 (en) 2019-12-18 2021-06-24 Glykos Biomedical Oy Stabile conjugate
AU2021205312A1 (en) 2020-01-09 2022-07-14 Mersana Therapeutics, Inc. Site specific antibody-drug conjugates with peptide-containing linkers
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
MX2023008000A (en) 2021-01-04 2023-07-13 Mersana Therapeutics Inc B7h4-targeted antibody-drug conjugates and methods of use thereof.
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
CA3216228A1 (en) 2021-06-09 2022-12-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
WO2023076881A1 (en) 2021-10-26 2023-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
GB202116442D0 (en) 2021-11-15 2021-12-29 Actome Gmbh High-efficacy labeling of antibodies with oligonucleotide labels
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080199905A1 (en) * 2003-12-05 2008-08-21 Goverment Of The Us, As Represented By The Secretary, Department Of Health And Human Services Catalytic Domains Of Beta(1,4)-Galactosyltransferase I Having Altered Metal Ion Specificity
US7482133B2 (en) * 2003-01-10 2009-01-27 The United States Of America As Represented By The Department Of Health And Human Services Catalytic domains of β(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1937035A (en) * 1930-10-20 1933-11-28 Westinghouse Elec Elevator Co Elevator safety device
US2897920A (en) * 1958-01-28 1959-08-04 Dresser Ind Emergency brake for elevator cars
US3282383A (en) * 1964-06-30 1966-11-01 Triax Co Free-fall safety brake
GB2252545A (en) * 1991-02-06 1992-08-12 Poon Otto L Bi-directional safety brake for elevator
US6446769B1 (en) * 2000-10-02 2002-09-10 Gregory A. Kangiser Braking apparatus for a linear motor driven load
EP1721858B1 (en) * 2005-05-09 2008-07-16 Dynatech, Dynamics & Technology, S. L. Catch system for a gradual bidirectional safety device
BRPI0601926B1 (en) * 2005-06-17 2018-06-12 Inventio Aktiengesellschaft BRAKE PARACHUTE DEVICE
EP1783086B1 (en) * 2005-11-08 2014-03-19 Dynatech, Dynamics & Technology, S. L. Catch system for a gradual bidirectional safety device

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7482133B2 (en) * 2003-01-10 2009-01-27 The United States Of America As Represented By The Department Of Health And Human Services Catalytic domains of β(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use
US20080199905A1 (en) * 2003-12-05 2008-08-21 Goverment Of The Us, As Represented By The Secretary, Department Of Health And Human Services Catalytic Domains Of Beta(1,4)-Galactosyltransferase I Having Altered Metal Ion Specificity

Also Published As

Publication number Publication date
US20060084162A1 (en) 2006-04-20
WO2004063344A2 (en) 2004-07-29
AU2009201883A1 (en) 2009-06-04
AU2004204463B2 (en) 2009-02-12
EP1587919A4 (en) 2006-10-11
CA2510550A1 (en) 2004-07-29
AU2004204463A1 (en) 2004-07-29
EP1587919A2 (en) 2005-10-26
US7482133B2 (en) 2009-01-27
WO2004063344A3 (en) 2005-05-19
JP2006518192A (en) 2006-08-10

Similar Documents

Publication Publication Date Title
US7482133B2 (en) Catalytic domains of β(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use
Nilsson Enzymatic synthesis of oligosaccharides
US8703459B2 (en) Catalytic domains of beta(1,4)-galactosyltransferase I having altered metal ion specificity
CN101415834B (en) Method of producing sialylated oligosaccharides
CA2493258C (en) Synthesis of oligosaccharides, glycolipids, and glycoproteins using bacterial glycosyltransferases
US6284493B1 (en) Method of synthesizing saccharide compositions
EP0619837B1 (en) A method for obtaining glycosyltransferases
US20030207406A1 (en) Method of transferring at least two saccharide units with a polyglycosyltransferase
JP2004528001A (en) Fucosylated recombinant glycopeptides in vitro
JP2005535280A (en) Remodeling of glycoproteins using endoglycanase
IL130964A (en) Practical in vitro sialylation of recombinant glycoproteins
JP6511045B2 (en) Process for mono- and bi-sialylation of glycoproteins using N-terminally truncated beta-galactoside alpha-2,6-sialyltransferase variants
JP2011167200A (en) H.pylori fucosyltransferase
WO2008143944A2 (en) Methods of glycosylation and bioconjugation
US20150018522A1 (en) Catalytic domains of beta(1,4)-galactosyltransferase i having altered metal ion specificity
US9938510B2 (en) Photobacterium sp. alpha-2-6-sialyltransferase variants
WO2006043305A1 (en) Method of enhancing enzymatic activity of glycosyltransferase
WO2023202991A2 (en) Cell-free enzymatic method for preparation of n-glycans
AU771407B2 (en) Practical in vitro sialylation of recombinant glycoproteins
Guerin et al. Preliminary crystallographic studies of glycogen synthase from Agrobacterium tumefaciens
MXPA97009505A (en) Method to transfer at least two units of success with a poliglicoslitransfer
JP2002306184A (en) Method for producing n-acetylglucosaminyl transferase
AU2004202707A1 (en) Practical in vitro sialylation of recombinant glycoproteins

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION